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SUMMARY 
 
Signal transducers and activators of transcription (Stats) comprise a family of 
transcription factors that are activated by various cytokines and growth factors. Seven 
mammalian Stat proteins exist and they all share a similar overall structure. Stat5 was 
originally identified as a transcription factor that regulates the β-casein gene in response to 
prolactin (PRL), but is activated also by several other ligands, including growth hormone, 
erythropoietin, interleukin-2 (IL-2), IL-3, and platelet-derived growth factor (PDGF). Stat 
proteins are latent in the cytoplasm until activated through receptor-mediated tyrosine 
phosphorylation leading to dimerization and nuclear translocation. In the nucleus, Stat dimers 
bind to DNA and initiate transcription of the target genes. In the case of cytokine receptors, 
Stat activation most often utilizes kinases of the Jak family. However, the mechanism of Stat 
activation in growth factor-stimulated signaling has remained elusive. In addition to the 
PDGF receptor (PDGFR), which is a tyrosine kinase itself, also cytoplasmic tyrosine kinases 
of Jak and Src families are activated upon PDGF stimulation. In our studies it was observed 
that the kinase responsible for Stat5 activation is the PDGFR kinase itself. 
The molecular mechanisms that underlie Stat5-mediated transcription are not fully 
understood, but these mechanisms involve interactions and cooperation with sequence 
specific transcription factors as well as with transcriptional coregulators. In mammary cells, 
the synergistic activation of transcription of the β-casein gene has been shown to be 
dependent on the interaction between Stat5, glucocorticoid receptor, and CCAATT/enhancer 
binding protein-β. Recently, the expression of a tudor and nuclease-like domains containing 
coactivator protein p100 was found to be abundant in the nuclei of mammary epithelial cells. 
The protein levels of p100 increased in response to lactogenic hormones during lactation and 
correlated with the induction of β-casein gene expression. These findings suggested a role for 
p100 in lactation. Our results showed that p100 interacts with Stat5 and enhances the Stat5-
mediated transcriptional activation, thus indicating that p100 functions as a coactivator for 
Stat5. In addition, PRL up-regulates p100 protein levels in mouse mammary epithelial cells. 
These results suggest the existence of a positive regulatory loop in PRL-induced transcription, 
where PRL stabilizes p100 protein, which in turn can cooperate with Stat5 in transcriptional 
activation.  
Stat activation is inhibited by dephosphorylation, but also by induced suppressors of 
cytokine signalling (SOCS) proteins, which can block Stat activation by inactivation of Jak, 
by blocking access of Stat to the receptor sites, or by targeting bound proteins to proteasomal 
degradation. Stat5 induces the expression of numerous proteins including β-casein, Cyclin D, 
Bcl-xL, Pim-1, c-Fos and c-Jun. Pim-1 is a serine/threonine kinase, which has been shown to 
be a survival factor for IL-3-dependent cells. In our studies IL-3-dependent FDCP myeloid 
cells that have enforced expression of Pim-1 exhibited inhibited Stat5 DNA-binding and 
tyrosine phosphorylation. Pim-1 was not able to phosphorylate Stat5 or directly bind to Stat5. 
Instead, Pim-1 cooperated with SOCS-1 and SOCS-3 to inhibit Stat5 activity. SOCS-3 and 
Pim-1 associated in vivo and Pim-1 phosphorylated SOCS-3. Our data suggest that Pim-1 
together with SOCS-1 and SOCS-3 are components of a negative feedback loop that allows 
Stat5 to inhibit its own activation.  
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INTRODUCTION 
1. Jak/Stat pathway 
Majority of the mammalian signal transduction processes are initiated as a result of 
interactions between ligand and receptor (reviewed in Kishimoto, 1994). These interactions 
result in biochemical changes, which are processed and delivered to the nucleus to cause 
changes in gene expression. Investigations of transcriptional responses to interferons (IFNs) 
led to the identification of Janus kinase-Signal transducer and activator of transcription 
(Jak/Stat) pathway. During the past decade, a large amount of evidence has accumulated to 
indicate that cytokines transmit their signals via a family of Jak tyrosine kinases and their 
downstream targets, Stats (reviewed in Darnell et al., 1994; Ihle, 1995; Schindler and Darnell, 
1995; Ihle et al., 1997). Stats were originally described as ligand-induced transcription factors 
in IFN-treated cells (reviewed in Darnell et al., 1994; Darnell, 1997). Subsequent studies 
showed that Stats play a critical role in signal transduction pathways associated with the large 
hematopoietic family of cytokines. Stats are also activated after activation of receptor tyrosine 
kinases (RTKs), such as epidermal growth factor receptor (EGFR) and platelet-derived 
growth factor receptor (PDGFR) (Leaman et al., 1996; Vignais et al., 1996; Valgeirsdottir et 
al., 1998). In addition, Stats are activated by hormones (like growth hormone; GH) (Silva et 
al., 1994; Bergad et al., 1995), and also the stimulation of several members of G-protein-
coupled receptors have been shown to lead to Stat activation (Marrero et al., 1995; Wong and 
Fish, 1998; Vila-Coro et al., 1999). Stat proteins are initially present in inactive forms in the 
cytoplasm. In the general model for the activation of Jak/Stat pathway, the activation cascade 
starts with the activation of receptor-bound Jak kinases following ligand stimulation and 
receptor dimerization (Figure 1). Jak kinases subsequently phosphorylate receptor at tyrosine 
residues. This phosphorylation recruits Stats to the receptor, after which Stats are 
phosphorylated, dimerized, and quickly translocated to the nucleus. In the nucleus, the dimers 
bind to specific sequences called γ-activated sequences (GAS) in the promoter regions of their 
target genes, and stimulate the transcription of these genes (reviewed in Schindler and 
Darnell, 1995; Darnell, 1997). 
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1.1. Members of Stat family 
Seven mammalian Stats exist (Stat1, 2, 3, 4, 5A, 5B and 6). Stat homologues have 
been identified also in a number of more primitive organisms, where they appear to transduce 
developmentally important signals. To date, homologs to mammalian Stats have been 
identified in amoebae (Dictyostelium discoideum), nematode (Caenorhabditis elegans), fruit 
fly (Drosophila melanogaster), malaria mosquito (Anopheles gambiae), frog (Xenopus laevis) 
and zebrafish (Danio rerio) (Aubry and Firtel, 1999; Barillas-Mury et al., 1999; Oates et al., 
1999; Zeidler et al., 2000; Pascal et al., 2001). Recently, a Stat homologous to Stat5 was 
identified in pufferfish (Tetraodon fluviatilis) (Sung et al., 2003). In Drosophila, the Jak/Stat 
pathway is genetically well characterized and has been shown to be important for growth, 
development, and differentiation of cells and tissues (Hou et al., 1996; 2002; Yan et al., 
1996a; 1996b). In mammals, the seven Stats are segregated to three clusters. Each cluster 
represents a tandem duplication. In mouse, Stat1 and Stat4 map to chromosome 1, while Stat2 
and Stat6 are located in chromosome 10. Stat3 and Stat5 are located in chromosome 11, but 
the Stat5 gene has undergone an additional duplication (i.e. Stat5A and Stat5B) more recently 
during evolution (Copeland et al., 1995).  
 
Stat1 and Stat2 
Research on IFN signaling pathways led to the discovery of the first members of Stat 
family, namely Stat1 and Stat2 (Fu, 1992; Fu et al., 1992; Schindler et al., 1992; Shuai et al., 
1992; Pearse et al., 1993; Veals et al., 1993; Shuai, 1994). IFNγ induces formation of Stat1 
homodimers, which initiate transcription of GAS-driven genes. IFNα and IFNβ lead to 
formation of Stat1 homodimers and also of Stat1/Stat2 heterodimers, which associate with the 
IRF-9 (p48) protein to form a complex called IFN-stimulated gene factor-3 (ISGF-3), and 
induce transcription of IFN-stimulated response element (ISRE)-driven genes. IFNγ activates 
Stat1 almost exclusively, and mice that lack Stat1 have no innate response to either viral or 
bacterial pathogens, because defence against these pathogens usually requires response to IFN 
(Durbin et al., 1996; Meraz et al., 1996). Although a number of cytokines and growth factors 
can activate Stat1, currently there are no major developmental deficits identified in these mice 
attributable to non-IFN signalling (Table 1). Stat1-deficient mice develop spontaneous and 
chemically-induced tumors more readily than wild-type animals, defining Stat1 as a tumor 
suppressor (Kaplan et al., 1998a). There is evidence that Stat1 activation commonly leads to 
antiproliferative and proapoptotic events, and this may partly explain why the lack of this 
protein in vivo leads to increased tumor formation (reviewed in Bromberg, 2000). 
Additionally, Stat1 controls the expression of proteins involved in antigen presentation, 
thereby affecting the immunogenicity of the tumor. The low levels of Stat1 in the nucleus of 
unstimulated cells suggest that Stat1 might cooperate with other transcriptional factors to 
regulate the basal expression of certain genes (reviewed in Schindler and Strehlow, 2000).  
Figure 1. Activation and inhibition of the Jak/Stat pathway. Cytokine binds to its receptor resulting in receptor 
dimerization, transphosphorylation of Jaks, and phosphorylation of the receptor. Stats bind to the 
phosphorylated receptor, are in turn phosphorylated, dimerize, and enter the nucleus where they initiate 
transcription. Some of the genes activated are SOCS family members (CIS, SOCS-1 and SOCS-3 in the 
figure), which in turn bind and deactivate Jaks and occupy receptor Stat-binding sites. SOCS proteins can also 
target proteins to degradation by ubiquitin-proteasome system (Ub). Tyrosine phophatase SHP-1 binds to the 
activated receptor before dephosphorylating the Jaks. A cytosolic protein-tyrosine phosphatase PTP1B also 
binds and deactivates Jaks. A nuclear phosphatase for Stats is indicated as N-PTP in the figure. PIAS
molecules modulate the activity of Stat dimers by preventing them from binding to DNA or inducing 
sumoylation (Su). 
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Despite being the second Stat cloned, Stat2 remains least well understood. Stat2 
represents a unique member of the Stat family, being the only Stat that does not bind to GAS 
elements following activation. Like Stat1-deficient mice, also mice lacking Stat2 are fertile, 
viable and develop normally (Park et al., 2000). However, similar to Stat1-deficient mice, 
Stat2-null mice are susceptible to viral infections. This is due to impaired IFN   /

 
responsiveness, supporting the idea that Stat2 plays an essential role in the ISGF-3 complex 
induced by IFNα (Table 1).  
 
Stat3  
Stat3 is ubiquitously expressed in most tissues and early during post-implantation 
(Duncan et al., 1997). Stat3 was originally identified as an acute-phase response factor, 
activated by IL-6, but Stat3 is also activated by many other cytokines (Akira et al., 1994). 
Stat3 is also involved in transformation. Stat3 protein is found activated in many cancerous 
cell lines and tumors (Bowman et al., 2000). Disruption of the stat3 gene leads to an early 
embryonic lethal phenotype (Takeda et al., 1997). Tissue-specific targeting of Stat3 has not 
been found to have major developmental consequences; however, other abnormalities are 
apparent (Table 1). Stat3-deficient T-cells and hepatocytes exhibit a poor response to IL-6 
(Takeda et al., 1998; Alonzi et al., 2001), whereas Stat3 deficiency in macrophages and 
neutrophils is associated with exaggerated production of cytokines presumably due to 
impaired IL-10 responsiveness (Takeda et al., 1999). Stat3-null mammary glands exhibit a 
significant delay in programmed cell death that occurs during cyclical mammary gland 
involution (Chapman et al., 1999). Finally, tissue-specific deletion of Stat3 in keratinocytes 
leads to defects in both skin and hair (Sano et al., 1999).  
 
Stat4 
Stat4 was identified by screening of cDNA libraries and sequence databases for 
homologues of Stat1 and Stat2 (Yamamoto et al., 1994). In contrast to other Stats, which are 
ubiquitously expressed, the expression of Stat4 was found to be limited to natural killer (NK) 
-cells, dendritic cells and T-lymphocytes. Stat4 is activated by IL-12, which plays a critical 
role in the development of the Th1 subset of T helper cells (versus Th2 cells). Stat4 knockout 
mice confirmed the important role of Stat4 in IL-12 signaling (Thierfelder et al., 1996; 
Kaplan et al., 1998b). As might be predicted, Stat4-deficient mice are resistant to autoimmune 
diseases characterized by a Th1 response (Chitnis et al., 2001) (Table 1). On the other hand, 
Stat4-deficient mice have increased susceptibility to infection with intracellular organisms 
(Tarleton et al., 2000). Stat4 was recently shown to be activated also by IL-23 (Parham et al., 
2002). 
 
Stat5  
Stat5 (Stat5A) was first identified as a PRL-induced mammary gland factor (MGF) 
(Gouilleux et al., 1994). Subsequent studies led to a discovery of two closely related 
sequences, Stat5A and Stat5B (Azam et al., 1995; Mui et al., 1995). These proteins share over 
90% identity and diverge only at their carboxy (C)-terminus. In addition to PRL, Stat5 
proteins are activated by many other cytokines and growth factors (Ihle, 1996; Darnell, 1997; 
Leonard and O'Shea, 1998). Both Stat5 proteins are ubiquitously expressed, but the 
expression profiles are different. Stat5A is the predominant form in mammary gland, whereas 
Stat5B is more prominently expressed in liver. In vitro studies with dominant negative Stat5 
mutants demonstrated that Stat5A and Stat5B display functional redundancy (Moriggl et al., 
1996). Despite these structural and functional similarities, Stat5A and Stat5B single knockout 
mice had remarkably distinct phenotypes (Table 1). Stat5A knockout mice have impaired 
mammary gland development due to loss of PRL responsiveness (Liu et al., 1997; Teglund et 
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al., 1998), whereas Stat5B-deficient mice have sexually dimorphic growth retardation due to 
defects in GH signaling (Udy et al., 1997; Teglund et al., 1998). The Stat5A/B double 
knockout mice exhibited a more severe phenotype. Many of the double knockout mice die 
within a few weeks of birth, are infertile, and have defective mammary gland development 
(Miyoshi et al., 2001) (Table 1). In addition, these mice are small and have reduced size of fat 
pads and reduced levels of insulin-like growth factor-1 (IGF-1). Stat5A/B double knockout 
mice have also hypocellular bone marrow, lymphopenia, neutrophilia, modest anemia, 
thrombocytopenia, reduced numbers of B-cell precursors and mature B-cells, and reduced 
responsiveness to IL-7 (Sexl et al., 2000; Bunting et al., 2002; Snow et al., 2002). In addition, 
NK-cells are absent, but thymic development is intact; however, peripheral T-cells from these 
mice express activation markers constitutively and have impaired in vitro proliferation 
(Matsumoto et al., 1999). Activated Stat5 has been found in several malignancies (Weber-
Nordt et al., 1996; Gouilleux-Gruart et al., 1997; Yu et al., 1997; Bovolenta et al., 2002). In 
hematopoietic cells, Stat5 has been demonstrated to play a critical role in regulating apoptosis 
(Onishi et al., 1998; Teglund et al., 1998; Nosaka et al., 1999; Socolovsky et al., 1999), and 
in promoting proliferation and cell cycle progression (Moriggl et al., 1999; Nieborowska-
Skorska et al., 1999). More information about Stat5 is presented in chapter 2. 
 
 
Stat6 
Stat6 is expressed in all tissues and was originally purified from the cell extracts as the 
IL-4-stimulated Stat (Hou et al., 1994). Stat6 functions in the adaptive immune system and is 
critical for Th2 differentiation (Hou et al., 1994). Stat6 is also activated by IL-13, which 
shares a receptor chain with IL-4 (Lin et al., 1995). IL-4 and IL-13 play an important role in 
regulating acquired immunity. In line with this, Stat6 knockout mice exhibit profound defects 
in their ability to develop Th2-cells (Kaplan et al., 1996; Shimoda et al., 1996; Takeda et al., 
1996) (Table 1). Stat6 is required for induction of IL-4-dependent gene expression leading to 
Th2-cell differentiation and IL-4-dependent B-cell proliferation (Shimoda et al., 1996; 
Takeda et al., 1996). Additionally, Stat6-deficient B-cells are unable to undergo class 
switching and produce IgE (Shimoda et al., 1996). Stat6 may be necessary for the down-
regulation of tumor immunosurveillance, since Stat6 deficiency is associated with resisted 
tumor reappearance (Terabe et al., 2000). 
 
ROLE OF STAT PROTEINS AS REVEALED BY GENE-TARGETING STUDIES IN MICE 
Stat1 Viable and fertile, impaired responses to interferons (IFNα/β and IFNγ); increased 
susceptibility to tumors 
Stat2 Viable and fertile; impaired responses to interferons (IFNα/β), reduced Stat1 expression 
in some tissues 
Stat3 Embryonic lethal. Conditional knockouts have multiple defects in adult tissues including 
impaired cell survival and impaired response to pathogens 
Stat4 Viable and fertile, impaired Th1 differentiation due to loss of IL-12 responsiveness 
Stat5A Viable and fertile, impaired mammary gland development due to loss of PRL 
responsiveness 
Stat5B Viable and fertile, impaired growth due to loss of GH responsiveness 
Stat5A/B Viable, female infertility, defective mammary gland development, reduced body mass in 
males and females, defective T-cell proliferation 
Stat6 Viable and fertile, impaired Th1 differentiation due to loss of IL-4 responsiveness 
 
Table 1.
 Phenotypes of Stat-deficient mice, adapted from Levy and Darnell, 2002; O'Shea et al., 2002. 
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1.2. Stat structure 
Stats are proteins of 750 to 850 amino acids that contain six structurally and 
functionally conserved domains (Figure 2). The amino (N)-terminal domain is conserved 
among the Stats and represents an independently folded and stable moiety (Vinkemeier et al., 
1996). The crystal structure of the N-terminus of Stat4 reveals a dimer (Vinkemeier et al., 
1998). Several studies suggest that this N-terminal dimerization promotes cooperativity of 
binding to tandem GAS elements (Vinkemeier et al., 1996; Xu et al., 1996b; Vinkemeier et 
al., 1998). Studies have also suggested that the N-terminal domain regulates nuclear 
translocation of Stats (Strehlow and Schindler, 1998) and can promote interaction with the 
transcriptional coactivator CBP(CREB-binding protein)/p300 (Zhang et al., 1996), the PIAS 
family proteins (Shuai, 2000), and receptor domains (Leung et al., 1995; Li et al., 1997; 
Murphy et al., 2000).  
The coiled-coil domain consists of four α-helices. The crystal structures of Stat1 and 
Stat3 reveal that this domain forms a large predominantly hydrophilic surface that is available 
for specific interactions with other helical proteins (Becker et al., 1998; Chen et al., 1998). 
Proteins interacting with the coiled-coil domain are many and include IRF-9, the transcription 
factor c-Jun, N-myc interactor (Nmi), and Stat3-interacting protein (StIP1) (Zhang et al., 
1999b; Zhu et al., 1999; Collum et al., 2000; Horvath, 2000). In addition, the coiled-coil 
domain is also implicated in receptor binding, tyrosine phosphorylation, and nuclear export 
(Begitt et al., 2000; Zhang et al., 2000).  
 
 
 
Figure 2. The domain structure of Stat contains six structurally and functionally conserved domains: N-terminal 
domain, coiled-coil domain, DNA-binding domain, linker domain, SH2 domain, and transactivation domain. 
 
The DNA-binding domain is a region of β-sheet structures connected by unstructured 
loops (Chen et al., 1998). Each Stat component of the dimer recognizes bases in the most 
proximal half GAS element. The cooperativity in DNA-binding is likely to be important in 
effective transcriptional activity, because the number of direct contact sites between amino 
acid residues and DNA are modest, accounting for dissociation constant in the nanomolar 
range. Interestingly, the conformation of DNA-binding domain is different before and after 
ligand stimulation and may therefore have still unknown functions (McBride et al., 2000). 
The linker domain connects the DNA-binding domain with the SH2 domain. The 
observations done with Stat1 crystal structure suggest that DNA-binding capacity can be 
regulated by structural changes in the SH2 domain as it binds to phosphotyrosine at the C-
terminus of another Stat protein (Chen et al., 1998) (Figure 3). The linker domain of Stat1 is 
also implicated in transcriptional regulation (Yang et al., 1999). The SH2 domain is the most 
highly conserved Stat domain. Stat dimerization depends on the interaction between the SH2 
domain of one Stat monomer and the tyrosine phosphorylated tail segment of the other 
monomer. The ability of SH2 domain to recognize specific phosphotyrosine motifs plays an 
essential role in several Stat signaling events; Stat homo- or heterodimerization, recruitment 
to the cytokine receptor through recognition of specific receptor phosphotyrosine motifs, and 
association with the activating Jak (reviewed in Shuai et al., 1994). All Stats except Stat2 
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have been shown to form stable homodimers. Additionally, many Stats can heterodimerize 
with other Stats through SH2-phosphotyrosine interaction (reviewed in Schindler and Darnell, 
1995). Although the Stat5 proteins do not heterodimerize with less related Stats, consistent 
with their SH2 domains more homologous overall than other Stats, it is logical that Stat5A 
and Stat5B form both homo- and heterodimers (Liu et al., 1996).  
The C-terminal transactivation domain (TAD) is poorly conserved among the Stats. 
This is in line with the ability of Stat-TAD to regulate unique transcriptional responses. The 
evidence that the C-terminus encodes TAD came from a comparative analysis of the full-
length Stat1 and an alternatively spliced isoform Stat1, which lacks the last 38 C-terminal 
amino acids (Schindler et al., 1992). The C-terminally truncated Stat1 was not able to drive 
transcription. C-terminally truncated isoforms have also been identified for Stat3, Stat4, Stat5, 
and Stat6 (Schindler and Strehlow, 2000; Sherman et al., 2002; Hoey et al., 2003), and they 
appear to function as dominant-negative regulators. The TAD region contains serine 
residue(s) that can modulate the transcriptional activity of Stats (reviewed in Decker and 
Kovarik, 2000). The TAD region has been characterized to be important in coregulator 
recruitment (Bhattacharya et al., 1996; Zhang et al., 1996; Pfitzner et al., 1998; Litterst and 
Pfitzner, 2002). 
 
 
Figure 3. The crystal structure of Stat1 homodimer in a complex with the DNA. Stat1 utilizes a DNA-binding 
domain with an immunoglobulin fold. The Stat1 dimer forms a C-shaped clamp around DNA that is stabilized 
by interactions between the SH2 domain of one monomer and the tyrosine-phosphorylated C-terminal segment 
of the other monomer. The phosphotyrosine-binding site of the SH2 domain in each monomer is coupled 
structurally to the DNA-binding domain, suggesting a potential role for the SH2-phosphotyrosine interaction in 
the stabilization of DNA-interacting elements. Reprinted from Chen et al., 1998, with permission from Elsevier, 
Copyright (1998). 
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1.3. Receptors and tyrosine kinases involved in Stat activation 
 
1.3.1. Cytokine receptors 
A family of soluble polypeptides, referred to as cytokines, controls hematopoietic cell 
proliferation and differentiation. Cytokines include interleukins (ILs), IFNs, colony-
stimulating factors, and erythropoietin (EPO) (reviewed in Metcalf, 1989). Hematopoietic 
cytokine receptors are transmembrane glycoproteins, composed of an extracellular ligand- 
binding domain, a hydrophobic transmembrane part, and an intracellular domain (reviewed in 
Ihle et al., 1994a; Silvennoinen et al., 1997) (Figure 4). Cytokine receptors can be organized 
into subgroups by the number of receptor subunits and the use of common signaling chains. 
Type I cytokine receptors include the gp130 family, the common γ chain (γc) family, the 
common β chain (βc) family, and the single chain family of the receptors (reviewed in 
Schindler and Strehlow, 2000). Type II cytokine receptors include receptors for IFNs and also 
receptors for IL-10 and IL-10-related cytokines (reviewed in Kotenko and Pestka, 2000). 
Type I receptors share similar basic structural features with each other (reviewed in Davies 
and Wlodawer, 1995; Leonard and Lin, 2000), and are characterized by the presence of four 
conserved cysteine residues, a WSXWS motif, and fibronectin type III modules in the 
extracellular domain. In addition, a Box1/Box2 region exists in the cytoplasmic domain.  
 
 
Figure 4. The general structure of receptors of the hematopoietic cytokine receptor family. The extracellular 
domains of type I cytokine receptors are characterized by a homologous region called the cytokine or 
hematopoietic receptor homology (CHR) domain. The N-terminus of the CHR usually contains two pairs of 
conserved cysteine residues, and the C-terminus contains a conserved WSXWS motif. The type II cytokine 
receptors have the similar extracellular domain structure as type I receptors, but they differ by a unique cysteine 
distribution and lack of the WSXWS motif. The cytoplasmic regions of the cytokine receptors are less conserved 
than the extracellular regions. The membrane-proximal parts show limited sequence similarity. The two 
conserved regions are referred as Box1 and Box2 motifs. 
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Members of the gp130 receptor family can be divided into two subclasses. One 
includes receptors for IL-6, IL-11, leukemia inhibitory factor (LIF), cardiotrophin-1 (CT-1), 
oncostatin M (OSM), ciliary neurotrophic factor (CNTF) and neurotrophin-1/B-cell-
stimulating factor-3 (NNT-1/BSF-3), which share a common receptor glycoprotein subunit 
called gp130 (reviewed in Hirano et al., 1994; Kishimoto, 1994; Taga, 1996). Receptors for 
G-CSF, leptin and IL-12 belong to the second group of the gp130 receptors, which are 
characterized by the employment of at least one gp130-like receptor chain. The shared gp130 
receptor chain associates with ligand-specific subunits (i.e. α-chains) to form functionally 
specific receptors. A receptor for the recently characterized heterodimeric cytokine IL-23 is 
composed of IL-12R β-chain and a novel cytokine receptor subunit, IL-23R (Frucht DM, 
2002). Other gp130 family members signal predominantly through Stat3, while IL-12- and 
IL-23-induced gene expressions are mediated mainly through Stat4 activation (reviewed in 
Akira, 1997; Ihle et al., 1997; Lankford and Frucht, 2003; Schindler and Strehlow, 2000) 
(Table 2). 
The γc family consists of receptors for IL-2, IL-4, IL-7, thymic stromal lymphopoietin 
(TSLP), IL-9, IL-13, IL-15, and IL-21 (reviewed in Demoulin and Renauld, 1998; Murata et 
al., 1998). Each of these receptors is composed of at least one specific ligand-binding chain 
(usually referred to as the α-chain) and a shared receptor component, the γc. Some receptors 
(e.g. for IL-2 and IL-15) include a third chain. While the receptors for IL-2, IL-7, TSLP, IL-9, 
IL-15 and IL-21 transmit signals mainly through activation of Stat5, the receptors for IL-4 
and IL-13 activate Stat6 more predominantly (reviewed in Demoulin and Renauld, 1998) 
(Table 2).  
The βc family of cytokine receptors include receptors for granulocyte/macrophage 
colony-stimulating factor (GM-CSF), IL-3, and IL-5 (reviewed in Miyajima et al., 1993). 
These receptors are a family of heterodimeric transmembrane proteins expressed by myeloid 
lineage cells. Each of these receptors has a unique ligand-binding α-chain and a shared βc. 
Signal transduction by these receptors is mediated primarily through activation of Jak2 and 
Stat5 (reviewed in Schindler and Strehlow, 2000) (Table 2).  
The family of single chain receptors consists of receptors for GH, EPO, PRL and 
thrombopoietin (TPO) (reviewed in Goffin and Kelly, 1997; Yoshimura and Misawa, 1998). 
The single chain receptors consist of one chain that homodimerizes upon ligand binding. They 
signal mainly through sequential activation of Jak2 and Stat5 (Gouilleux et al., 1995; Nagata 
and Todokoro, 1995) (Table 2). 
Type II cytokine receptors include: IFNγ, IFNαs/β/ω/limitin, IL-10, IL-19, IL-20, IL-
22, and IL-24. Type II cytokine receptors consist of at least two different subunits, which are 
both used in signaling, but only one binds the cytokine (reviewed in Kotenko and Pestka, 
2000). The IFNα receptor associates with Jak1 and Tyk2 to mediate IFN-dependent gene 
transcription. This entails the activation of two distinct Stat-dependent signaling pathways, 
ISGF-3 and Stat1 homodimers. Stat3 homodimers and Stat1/Stat3 heterodimers are also 
activated, but their role in signaling remains to be elucidated. Cellular responses following 
IFNγ stimulation are mediated through the recruitment of Stat1 to the IFN receptor 1 (IFNR1) 
chain and its subsequent activation by Jak1/Jak2 (Greenlund et al., 1994; 1995). The IL-10 
receptor signals through sequential activation of Tyk2/Jak1 and Stat1/Stat3 (Finbloom and 
Winestock, 1995). IL-22 is an IL-10-related cytokine, which induces activation of Stat1, 
Stat3, and Stat5 (Lejeune et al., 2002). IL-20 appears to signal through Stat3 (Blumberg et al., 
2001) (Table 2).  
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LIGAND JAKs ACTIVATED STATs ACTIVATED 
IFN family   
IFNα/β/ω/Limitin Jak1, Tyk2  Stat1, Stat2, Stat3-Stat6 
IFN-γ Jak1, Jak2 Stat1, Stat2, Stat5 
IL-10 Jak1, Tyk2  Stat1, Stat3 
IL-19, IL-20, IL-24 ? Stat1, Stat3 
IL-22 Jak1, Tyk2 Stat1, Stat3, Stat5 
Gp130 family 
  
IL-6, OSM, LIF,  Jak1, Jak2 Stat1, Stat3, Stat5 
IL-11, CNTF, CT-1, NNT-
1/BSF-3 
Jak1, Jak2 Stat1, Stat3 
G-CSF Jak1, Jak2 Stat1, Stat3, Stat5 
Leptin Jak2 Stat1, Stat3, Stat4, Stat5 
IL-12 Jak2, Tyk2  Stat1, Stat3, Stat4, Stat5 
IL-23 Jak2, Tyk2 Stat1, Stat3, Stat4, Stat5 
γc family 
  
IL-2 Jak1, Jak3 Stat1, Stat3, Stat5 
IL-7 Jak1, Jak3 Stat1, Stat5 
IL-9 Jak1, Jak3 Stat3, Stat5 
IL-15 Jak1, Jak3 Stat5, Stat6 
TSLP none Stat5 
IL-21 (Jak1), Jak3 Stat3, Stat5 (Stat1) 
IL-4 Jak1, Jak3 Stat3, Stat5, Stat6 
IL-13 Jak1, Jak2, Tyk2 Stat3, Stat5, Stat6 
βc family 
  
IL-3, IL-5, GM-CSF Jak2 Stat5 (+Stat1, Stat3, Stat6 
for IL-3) 
Single chain family 
  
EPO, PRL Jak2 Stat1, Stat3, Stat5 
GH Jak1, Jak2 Stat1, Stat3, Stat5 
TPO Jak2, Tyk2 Stat1, Stat3, Stat5 
Growth factors   
EGF Jak1, Jak2 Stat1, Stat3, Stat5 
PDGF Jak1, Jak2, Tyk2 Stat1, Stat3, Stat5, Stat6 
CSF-1 Tyk2, Jak1 Stat1, Stat3, Stat5 
HGF Jak2 Stat1, Stat3, Stat5 
VEGF ? Stat1, Stat3, Stat5, Stat6 
Insulin none Stat1, Stat3, Stat5 
IGF-1 Jak1, Jak2, Tyk2 Stat3 
SCF Jak2 Stat1, Stat5 
FGF Jak2 Stat1, Stat3 
G-proteins   
Angiotensin II AT1 Jak2, Tyk2 Stat1, Stat2, Stat5 
LH Jak2 Stat1, Stat5 
Serotonin Jak2 Stat3 
 
Table 2. Cytokines, growth factors and G-proteins and their substrate Jaks and Stats. Abbreviations: OSM, 
oncostatin M; LIF, leukemia inhibitory factor; CNTF, ciliary neurotrophic factor; CT-1, cardiotrophin-1; NNT-
1/BSF-3, neurotrophin-1/B-cell-stimulating factor-3; TPO, thrombopoietin; and TSLP, thymic stromal 
lymphopoietin. Adapted from Grimley et al., 1999; Schindler and Strehlow, 2000. 
 
 17 
1.3.1.1. Stat activation by cellular tyrosine kinases 
Molecular cloning of cytokine receptors and subsequent structure-function studies 
have revealed that unlike growth-factor receptors, cytokine receptors lack a cytoplasmic 
kinase domain. However, the interaction of a cytokine with its receptor induces rapid tyrosine 
phosphorylation of the the receptor and a variety of cellular proteins, suggesting that these 
receptors transmit their signals through cellular tyrosine kinases (reviewed in Ihle, 1994). 
Cytokine receptors have been shown to rely on members of the Jak family of tyrosine kinases 
to provide this activity (reviewed in Ihle et al., 1994b). Jaks associate also with the receptor 
tyrosine kinases and with G-protein-coupled receptors (Marrero et al., 1995; Sasaguri et al., 
2000). There are four members of the Jak family in mammals, Jak1, Jak2, Jak3, and Tyk2 
ranging in molecular weight from 110 to 140 kDa. Jak1, Jak2 and Tyk2 are ubiquitously 
expressed, whereas the expression of Jak3 is more restricted. Jak3 is expressed in the cells of 
hematopoietic and lymphoid lineages, in vascular smooth muscle cells, and in endothelium 
(Kawamura et al., 1994; Rane and Reddy, 1994; Musso et al., 1995; Tortolani et al., 1995; 
Gurniak and Berg, 1996; Verbsky et al., 1996). Jaks are usually constitutively associated with 
the membrane proximal domain of the cytokine receptors (reviewed in Ihle, 2001). Ligand 
binding promotes the dimerization of receptors into an active conformation (reviewed in 
Wells and de Vos, 1996). The activation is believed to lead to close approximation of 
cytoplasmic receptor tails, enabling the transphosphorylation (i.e. activation) of the receptor-
associated Jaks. Activated Jaks then phosphorylate specific tyrosine motifs present in the 
receptor intracellular domains, which in turn recruit Stats and other SH2 domain-containing 
signaling molecules to the receptor.  
 
 
Figure 5.
 The domain structure of Jak kinases. Jak kinases possess a kinase domain (JH1) at the C-terminus, a 
pseudokinase domain (JH2), an SH2-like domain (JH3-JH4), and a FERM domain (JH4-JH7). 
 
Jak sequence consists of seven regions of high homology, JH1-JH7, where JH1 has 
been shown to encode a kinase domain and JH2 a pseudokinase domain (Figure 5). The 
conserved kinase domain exhibits classical features of a tyrosine kinase (reviewed in Hubbard 
and Till, 2000), while the pseudokinase domain has all the structural features of a bona fide 
tyrosine kinase, but it lacks catalytic activity. There is growing evidence that the 
pseudokinase domain regulates the activity of the kinase (Luo et al., 1997; Barahmand-Pour 
et al., 1998; Saharinen and Silvennoinen, 2002; Saharinen et al., 2003). The N-terminal Jak 
region is somewhat divergent between family members. The N-terminus has been implicated 
in receptor association and appears to play an important role in determining the specificity of 
this binding (Leonard and O'Shea, 1998). The JH3-JH4 region shares some similarity with 
SH2 domains, and the JH4-JH7 region constitutes a FERM domain (Four-point-one, Ezrin, 
Radixin, Moesin) (Girault et al., 1998; Kampa and Burnside, 2000). Notably, the FERM 
domain was identified in the interactions between Jaks and other kinases (Miyazaki et al., 
1998; Zhu et al., 1998). In addition, the FERM domain of Jak1 may be critical for interaction 
with the gp130 receptor chain (Hilkens et al., 2001). Recent studies suggested a novel role for 
the Jak3 FERM domain in maintaining a functional kinase domain (Zhou et al., 2001).  
In addition to Jak kinases, also several other tyrosine kinases are activated by cytokine 
and growth factor receptors. Src-family members such as Src, Lck, Hck, Lyn, Fyn, and Fgr 
have been linked to Stat activation (Lund et al., 1997; Yu et al., 1997; Schreiner et al., 2002). 
However, it has remained somewhat unclear whether these kinases are able to activate Stats 
directly or whether they function e.g. through Jak kinases (Campbell et al., 1997). Other 
kinases implicated in Stat activation include: Etk/Bmx, a tyrosine kinase of Tec family 
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kinases, which is able to activate Stat1, Stat3 and Stat5 (Saharinen et al., 1997; Wen et al., 
1999), the focal adhesion kinase (FAK), which can activate Stat1 (Xie et al., 2001), and the 
nonreceptor tyrosine kinase Fes, which has the ability to bind and activate Stat3 in response to 
GM-CSF (Park et al., 1998).  
 
1.3.2. Oncogenic tyrosine kinases in Stat activation 
In contrast to normal signaling, in which Stat activation is rapid and transient and 
depends on ligand stimulation, constitutive signaling by Stats has been associated with 
malignant progression. In tumor cells, constitutive activation of Stats is linked to persistent 
activity of tyrosine kinases. Such oncogenic tyrosine kinases are often activated as a 
consequence of permanent ligand/receptor engagement in autocrine or paracrine cytokine and 
growth factor signaling or represent autonomous constitutively active enzymes as a result of 
genetic alterations found in tumor but not in normal cells. In mammalian cells, the original 
report demonstrating that Stats are constitutively activated in cells stably transformed by a 
specific oncoprotein, linked activation of the oncogenic Src tyrosine kinase to the activation 
of Stat3 (Yu et al., 1995). A TEL/Jak2 fusion (fusion of the Jak2 protein to the Ets family 
transcription factor TEL) has been shown to result in Stat activation and myeloproliferative 
disease (Ho et al., 1999; Lacronique et al., 2000), and both TEL/Jak2 and TEL/Abl induce the 
activation of Stat1 and Stat5 in human leukemia (Wilbanks et al., 2000). In addition, both the 
cell transformation by oncogenic tyrosine kinase v-Abl and the expression of Bcr-Abl 
oncogenic fusion protein, lead to the activation of Stat1 and Stat5 in chronic myelogenous 
leukemia (Danial et al., 1995; Carlesso et al., 1996). Fibroblast transformation by v-Fps 
correlates with potent activation of endogenous Stat3 (Garcia et al., 1997). Also the 
expression of the anaplastic lymphoma kinase (ALK) induces constitutive phosphorylation of 
Stat3 (Zamo et al., 2002). In addition to cellular oncogenes, Stat5 is activated by oncogenic 
receptor tyrosine kinases or oncogenic fusions of the receptors like the TEL/PDGFβR and 
Huntingtin interacting protein 1 (HIP1)/PDGFβR (Okuda et al., 1996; Ross et al., 1998; Ross 
and Gilliland, 1999; Wilbanks et al., 2000; Sternberg et al., 2001). Stat5 is also activated in 
fish melanoma cells by a melanoma-inducing EGFR-related receptor Xmrk (Morcinek et al., 
2002). 
 
CELL TYPE ONCOGENIC PROTEINS ACTIVATED STATs 
Fibroblast cells v-Src, c-Src Stat3 
 v-Fps (Fes) Stat3 
 v-Sis (PDGF) Stat3 
 Polyoma virus middle T antigen Stat3 
 v-Ros Stat3 
 IGF-1 receptor Stat3 
 c-Eyk, v-Eyk Stat1, Stat3 
Myeloid cells v-Src Stat1, Stat3, Stat5 
T-cells Lck Stat3, Stat5 
Mammary/lung epithelial cells v-Src Stat3 
 Etk/Bmx Stat1, Stat3, Stat5 
Gallbladder adenocarcinoma 
cells 
v-Src Stat3 
Pre-B lymphocytes v-Abl Stat1, Stat5 
Erythroleukemia/blast 
cells/Basofils/mast cells 
Bcr-Abl Stat1, Stat5 
Primary bone marrow cells Bcr-Abl Stat5 
 
Table 3.
 Stat activation by oncogenic kinases, modified from Bowman et al., 2000. 
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1.3.3. Receptor tyrosine kinases 
RTKs are composed of an extracellular ligand binding domain, followed by a single 
transmembrane domain and a cytoplasmic domain containing a conserved protein tyrosine 
kinase core, flanked by regulatory sequences (reviewed in Hubbard and Till, 2000) (Figure 6). 
Ligand binding to RTKs promotes receptor dimerization and subsequent activation of 
intrinsic tyrosine kinase activity that results in transphosphorylation of specific tyrosine 
residues (reviewed in Weiss and Schlessinger, 1998). Phosphorylation of a conserved tyrosine 
residue inside the kinase domains leads to an increase in the catalytic efficiency of the RTK. 
The phosphorylated tyrosine residues located outside the kinase domain serve as docking sites 
for an array of intracellular signaling molecules containing SH2 domains (reviewed in 
Pawson, 2002). These activated proteins then initiate signaling cascades resulting in 
activation of transcription factors that determine a variety of cell responses, including 
mitogenesis, migration, and differentiation. 
 
 
 
PDGF-αR  VEGFR-1   FGFR-1       TIE     ErbB1/EGFR     INSR   MET 
PDGF-βR  VEGFR-2   FGFR-2       TEK     ErbB2     IGF-1R RON 
CSF-1      VEGFR-3   FGFR-3      ErbB3     IRR 
KIT      VEGFR-4   FGFR-4      ErbB4 
FLT3 
 
Figure 6. The human RTK families involved in the activation of Stats. RTKs are composed of an extracellular 
ligand-binding domain, followed by a single transmembrane domain and a cytoplasmic domain containing a 
conserved protein tyrosine kinase. The prototypic receptor for each family is indicated above the receptor, and 
the known members are listed below. Abbreviations of the prototypic receptors: PDGFR, platelet-derived growth 
factor receptor; VEGFR, vascular endothelial growth factor receptor; FGFR, fibroblast growth factor receptor; 
TIE, tyrosine kinase receptor; EGFR, epidermal growth factor receptor; InsulinR, insulin receptor; HGFR, 
hepatocyte growth factor receptor. Other abbreviations: IgD, immunoglobulin-like domain; AB, acidic box; 
EGFD, epidermal growth factor-like domain; CRD, cystein-rich domain; FNIII, fibronectin type III-like domain. 
Adapted from Blume-Jensen and Hunter, 2001. 
 
 
RTKs for growth factors, such as receptors for PDGF, EGF, stem cell factor (SCF), 
hepatocyte growth factor (HGF), insulin, vascular endothelial growth factor (VEGF), and 
IGF-1, have been implicated in Stat activation. PDGFs exert their effects on target cells by 
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activating two structurally related tyrosine kinase receptors. Each α- and β-receptor (PDGF 
α-R and PDGF β-R) contains five immunoglobulin-like (Ig-like) domains in their 
extracellular part, and an intracellular tyrosine kinase domain that contains a characteristic 
inserted sequence without homology to kinases (Escobedo and Williams, 1988) (Figure 6). 
PDGFR activates Stat1, Stat3, Stat5, and Stat6 (Choudhury et al., 1996; Patel et al., 1996; 
Vignais et al., 1996; Valgeirsdottir et al., 1998) (Table 2). Same set of Stat proteins is 
activated by endothelial receptor tyrosine kinases (VEGFRs) 1-3, which resemble PDGFRs in 
structure (Pajusola et al., 1992; Terman et al., 1992; Enaida et al., 1999; Korpelainen et al., 
1999; Bartoli et al., 2000) (Figure 6). The second family of endothelial RTKs consists of Tie-
1 and Tie-2 (Tek) (Partanen et al., 1992; Dumont et al., 1993; Ziegler et al., 1993). The FGF 
family of receptors comprises of four structurally related members, FGFR1, FGFR2, FGFR3, 
and FGFR4. These receptors also exhibit Ig-like domains in their structure (Johnson and 
Williams, 1993; Partanen et al., 1993), and activate Stat1 and Stat3 (Hart et al., 2000; Sahni et 
al., 2001). The EGF (ErbB) RTK family consists of four homologous members; EGFR 
(ErbB1), ErbB2 (Neu), ErbB3, and ErbB4 (reviewed in Boulougouris and Elder, 2001) 
(Figure 6), which activate Stat1, Stat3, and Stat5 (Ruff-Jamison et al., 1993; 1994; Leaman et 
al., 1996; Gallego et al., 2001). The insulin receptor (InsR) is a heterotetrameric membrane 
protein that consists of two identical α- and β- subunits (reviewed in Czech, 1985; Canivet et 
al., 1992) (Figure 6). The activation of InsR results in activation of Stat1, Stat3, and Stat5 
(Ceresa and Pessin, 1996; Chen et al., 1997; Velloso et al., 1998). Stat3 is activated by HGFR 
(MET) (Schaper et al., 1997; Boccaccio et al., 1998), which is the prototypic member of a 
subfamily of heterodimeric receptor tyrosine kinases including also receptors called Ron and 
Sea (reviewed in Comoglio and Boccaccio, 1996). The structure of these receptors is 
characterized with a highly glycosylated and entirely extracellular α-subunit, as well as a β-
subunit with a large extracellular region, a membrane-spanning segment, and an intracellular 
tyrosine kinase domain (Weidner et al., 1993; Zhen et al., 1994) (Figure 6).  
  
 
1.3.3.1. PDGF and PDGFR 
PDGF is made up as a homo- or heterodimer of disulfide-bonded polypeptide chains. 
The chains are synthesized as precursor molecules that undergo proteolytic processing 
(Ostman et al., 1991). PDGF is a major mitogen for fibroblasts, smooth muscle cells, and 
many other cells, and PDGF has been shown to regulate cell proliferation, survival and 
chemotaxis in vitro (reviewed in Heldin and Westermark, 1999). PDGF- and PDGFR-targeted 
mice have shown that PDGF has important functions as a paracrine growth factor in 
development (Leveen et al., 1994; Bostrom et al., 1996; Betsholtz and Raines, 1997). 
Overactivity of PDGF has been linked to different types of disorders, including 
atherosclerosis, fibrotic diseases, and malignancies (reviewed in Heldin and Westermark, 
1999). The transforming oncogene sis encodes a PDGF-like growth factor, which transforms 
cells by an autocrine mechanism. For almost two decades, PDGF-AA, -BB and -AB were 
thought to be the only members of the PDGF family. Recently, two additional PDGF 
polypeptide chains were discovered, namely PDGF-C and PDGF-D (Ding et al., 2000; Li et 
al., 2000; Bergsten et al., 2001; LaRochelle et al., 2001). Dimeric PDGF isoforms dimerize 
receptors by binding two receptors simultaneously (Bishayee et al., 1989; Heldin et al., 1989), 
resulting in αα-receptor and ββ-receptor homodimers, and αβ-receptor heterodimers. These 
three receptor combinations transduce overlapping but not identical cellular signals. The 
phosphorylation of a conserved tyrosine residue inside the kinase domains (Tyr849 in α-R 
and Tyr857 in β-R) leads to an increase in the catalytic activity of the kinases (Kazlauskas 
and Cooper, 1989). A large number of SH2 domain proteins have been shown to bind to 
docking sites in α- and β-receptors (reviewed in Williams et al., 1991; Heldin et al., 1998). 
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Some of these proteins are enzymes, like the members of tyrosine kinase families of Src and 
Jak, tyrosine phosphatase SHP-2, and a GTPase-activating protein (GAP) for Ras, whereas 
other molecules like Grb2, Grb7, Nck, Shc, and Crk have adapter functions (reviewed in 
Heldin, 1997).  
 
 
2. Stat5 
2.1. Regulation of Stat5 activity 
The Jak/Stat pathway is important for many responses including differentiation, 
proliferation, and oncogenesis. It is, therefore, not surprising that numerous regulatory layers 
exist to modulate this signaling pathway. The effect of the negative and positive regulatory 
processes determines the rate at which Stat signals are transduced. Stat signals are down-
regulated at several points in the signaling cascade including the receptors, Jaks, and the Stat 
molecules themselves.  
 
2.1.1. Mutations and deletions 
A constitutively active Stat5A mutant (Stat5A1*6), which renders IL-3-dependent cell 
lines IL-3-independent, was found by screening randomly mutated Stat5As (Onishi et al., 
1998). In addition to inducing IL-3-independent proliferation, this constitutively active Stat5 
induced apoptosis and differentiation in the same cell line after IL-3 stimulation (Nosaka et 
al., 1999). Stat5A1*6 showed markedly elevated DNA-binding and transcriptional activities 
with stable tyrosine phosphorylation and nuclear accumulation. Stat5A1*6 harbors two point 
mutations; one in the TAD and other in the DNA-binding domain. The same results as with 
the 1*6 mutant Stat5A were obtained with the 1*6 mutant Stat5B (Onishi et al., 1998), 
indicating that the biological activities of the mutant Stat5A are not specific to the 1*6 mutant 
of Stat5A and will reflect physiological functions of Stat5. Another constitutively active Stat5 
mutant (Stat5A-Asn642His) has an asparagine-to-histidine mutation very close to the 
phosphotyrosine-binding site in the SH2 domain and has identical phenotype as the mutant 
Stat5A1*6 (Ariyoshi et al., 2000). The mutation in Stat5A-Asn642His resulted in restoration 
of the conserved critical histidine, which is involved in the binding of phosphotyrosine in the 
majority of SH2-containing proteins. Pim-1 and bcl-xL are genes induced by Stat5 (Lilly and 
Kraft, 1997; Packham et al., 1998; Thomas et al., 1998) and were expressed even in the 
absence of IL-3 in Ba/F3 cells expressing Stat5A-Asn642His. It is likely that this constitutive 
induction of genes important for proliferation and differentiation induces IL-3-independent 
cell growth of the Ba/F3 cells as well as in Ba/F3 cells expressing Stat5A1*6 (Nosaka et al., 
1999). Altogether, it seems that the activation of Stat5A1*6 and Stat5A-Asn642His mutants 
mimics the physiological activation of Stat5. 
Functionally distinct C-terminally truncated Stat isoforms have been reported. 
Naturally occurring truncated Stat1 and Stat3 bind DNA but fail to activate transcription as 
independent factors (Muller et al., 1993; Caldenhoven et al., 1996). Also naturally occurring 
C-terminally truncated Stat5 isoforms have been identified in several different cell types 
(Azam et al., 1995; Rosen et al., 1996; Kirken et al., 1997). A number of studies have clearly 
shown that the truncated Stat5 is the predominant phosphorylated Stat5 form observed after 
IL-3, GM-CSF, or EPO stimulation in early hematopoietic cells (Azam et al., 1995; Mui et 
al., 1995; Rosen et al., 1996). Significantly, these results were observed in both mice and 
humans, and with both primary cells and established cell lines. As compared to the primary 
forms of Stat5A and Stat5B, with molecular weights of 94 kDa (Stat5Aα) or 92 kDa 
(Stat5Bα), shortened Stat5 variants (Stat5Aβ and Stat5Bβ) exhibit molecular weight of 
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approximately 80kDa. As a general feature, truncated Stat5 isoforms lack a functional TAD 
and act as dominant negative inhibitors of Stat5-dependent transcription. They remain 
tyrosine phosphorylated and bound to GAS sites for longer periods of time than the full-
length Stat5 isoforms, suggesting that the C-terminal sequences may affect the interaction 
with a tyrosine phosphatase (Moriggl et al., 1996; 1997). In addition, it has been speculated 
that these variants are able to inhibit transcription by recruiting nuclear corepressors to gene 
promoters (Nakajima et al., 2001). Previous studies have shown that the truncated Stat5 
proteins are unable to transactivate cis and osm (Mui et al., 1996; Wang et al., 1996); two 
target genes shown to be up-regulated by Stat5 in early hematopoiesis. Azam and coworkers 
have verified that cells expressing exclusively Stat5β show a delayed and reduced activation 
of these two genes (Azam et al., 1995). Previous studies on the C-terminally truncated 
isoforms of Stat1 and Stat3 have established the precedent that truncated Stats are generated 
by alternative splicing (Muller et al., 1993; Schaefer et al., 1995; Yan et al., 1995; 
Caldenhoven et al., 1996). It has been shown that also the Stat5β form can be generated from 
an alternatively spliced message (the last intron remaining unspliced) (Wang and Yu-Lee, 
1996), consistent with transcripts detected in rat liver and mammary glands (Kazansky et al., 
1995; Ripperger et al., 1995). More recent studies have suggested that Stat5 truncations can 
also be generated by proteases; since a nucleus-associated serine protease that cleaves 
activated Stat5α to generate Stat5β was found to be present in early hematopoietic cells 
(Azam et al., 1995; Meyer et al., 1998). Recently, Oda and coworkers found that calpain, a 
ubiquitously expressed cysteine protease, also trims Stat5 within the C-terminus (Oda et al., 
2002). The identification of protease activity in several cell lines that are believed to represent 
earlier stages in myeloid differentiation suggests that the protease activity may be involved in 
the regulation of lineage-specific Stat5 signaling.  
 
 
2.1.2. Serine phosphorylation 
Tyrosine phosphorylation regulates the dimerization of Stats and is an essential 
prerequisite for the establishment of the classical Jak/Stat signaling pathway. However, most 
vertebrate Stats contain a second phosphorylation site within their C-terminus. The 
phosphorylated residue is a serine contained within a proline-serine-methionine-proline 
(PSMP) motif, and in the majority of situations its mutation to alanine alters transcriptional 
activity. Initial studies demonstrated the positive effect of Ser727 phosphorylation on 
transcriptional activity in Stat1 and Stat3 (Wen et al., 1995; Zhang et al., 1995), but more 
recent studies indicated that serine phosphorylation enhances also transcriptional activity of 
Stat4 (Visconti et al., 2000). Also Stat5 and Stat6 are phosphorylated on serine (Kirken et al., 
1997; Pesu et al., 2000; Wick and Berton, 2000), but enhanced transcriptional activity has not 
convincingly been demonstrated. In PRL-stimulated cells, both Stat5A and Stat5B are 
phosphorylated on a conserved serine residue (Ser725 in Stat5A and Ser730 in Stat5B) 
located within a PSP sequence, which corresponds in location to the PSMP serine 
phosphorylation sequence of Stat1, -3, and -4 (Yamashita et al., 1998). Stat5A is additionally 
phosphorylated on Ser779 (Pircher et al., 1999; Beuvink et al., 2000). The mitogen-activated 
protein kinase (MAPK) cascade is one candidate that could mediate serine phosphorylation on 
Stat5 (Pircher et al., 1997; 1999; Yamashita et al., 1998). Serine phosphorylation of Stat5A 
was not found to enhance Stat5A-mediated signaling in response to IL-2 (Xue et al., 2002), 
and no difference in PRL-stimulated Stat5 reporter gene activity was seen with serine-to-
alanine mutant forms of Stat5B (Ser730Ala) or Stat5A (Ser725Ala, Ser779Ala, or the 
Ser725,779Ala double mutant) compared with the corresponding wild-type Stat5 forms 
(Yamashita et al., 1998; Beuvink et al., 2000). In another study, serine phosphorylation has 
been shown to inhibit Stat5A activation following PRL stimulation. Surprisingly, 
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costimulation of glucocorticoid receptors completely reversed this suppressive effect of 
Stat5A serine phosphorylation, and suggested that serine phosphorylation might in some cases 
limit the activity of Stat5A in the absence of proper coactivation (Yamashita et al., 2001). 
Delayed tyrosine dephosphorylation and sustained DNA-binding activity were, however, 
reported for Stat5A-Ser725Ala in cells stimulated with PRL, suggesting that Ser725 
phosphorylation has an impact on signal duration (Beuvink et al., 2000).  
 
 
2.1.3. Dephosphorylation 
Shp-2 is a SH2 domain-containing tyrosine phosphatase that is widely expressed in all 
tissues and appears to be involved in multiple signaling pathways as a positive or a negative 
regulator (Feng et al., 1994; Neel and Tonks, 1997). Shp-2 has recently been shown to be a 
phosphatase for Stat5 (Aubert et al., 2003). Shp-2 interacted with Stat5A in a tyrosine 
phosphorylation-dependent manner and overexpression of Shp-2 impaired EPO-induced 
tyrosine phosphorylation of Stat5A. In addition, Shp-2 deficiency dramatically delayed 
dephosphorylation of Stat5A following cytokine removal. Nonetheless, in Shp-2-deficient 
cells, Stat5A is still dephosphorylated, albeit the process is delayed. It is therefore possible 
that there is another phosphatase(s) involved in the dephosphorylation of Stat5A. Previous 
studies have suggested that cytoplasmic protein-tyrosine phosphatase 1B (PTP-1B) negatively 
regulates the Stat5 activation in PRL-mediated signaling pathway (Aoki and Matsuda, 2000), 
and that serine/threonine protein phosphatase 2A (PP2A) plays a negative regulatory role in 
regulating IL-3 signaling by interacting with Stat5 and dephosphorylating it (Yokoyama et al., 
2001). Given the fact that these phosphatases are mainly distributed in the cytoplasm, it is 
reasonable to assume that the dephosphorylation of Stat5A primarily occurs in the cytoplasm. 
In this regard, it is interesting that a recently identified Stat1 phosphatase, T-cell protein-
tyrosine phosphatase TC-PTP, which dephosphorylates Stat1 in both the nucleus and 
cytoplasm (ten Hoeve et al., 2002), has also been reported to be a potential negative regulator of 
the PRL-mediated signaling pathway by dephosphorylating Stat5A and Stat5B in the nucleus 
(Aoki et al., 2002). 
 
 
2.1.4. Suppressors of cytokine signaling (SOCS)  
Currently there are eight known members (SOCS-1-7 and CIS) in the suppressors of 
cytokine signaling SOCS family, and many of the members have been implicated in the 
regulation of Stat5 signaling. A central SH2 domain and a unique motif in their C-terminus, 
which has been designated as a SOCS box, characterize SOCS proteins (Figure 7). 
Interactions between the SOCS box, elongins B and C, and the ubiquitin-proteasome system 
appear to influence the rate of SOCS protein degradation (Kamura et al., 1998; Zhang et al., 
1999a). The mRNA for SOCS proteins is found at low levels in different cells or tissues 
(reviewed in Starr et al., 1997; Chen et al., 2000; Krebs and Hilton, 2000; Yasukawa et al., 
2000). A wide range of cytokines such as PRL, GH, and ILs induces the expression of SOCS. 
In most cases, however, there is no correlation between a particular cytokine and the SOCS 
mRNAs it can induce. Indeed, cytokine induction of socs genes often varies with respect to 
the cell line or tissue. It is now apparent that the Stat proteins contribute significantly to the 
transcriptional up-regulation of the socs genes (reviewed in Chen et al., 2000; Krebs and 
Hilton, 2000; Yasukawa et al., 2000). Induction of SOCS-1 transcription by IFNγ is mediated 
by Stat1 (Saito et al., 2000), but binding sites for Stat3 and Stat6 are also found from the 
SOCS-1 promoter (reviewed in Krebs and Hilton, 2000). The CIS promoter contains four 
Stat5-binding sites, which are required for the EPO-mediated cis gene activation (Matsumoto 
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et al., 1997). Also a role for Stat5B in the regulation of socs-2 and socs-3 gene expression in 
liver has been suggested (Davey et al., 1999).  
 
 
 
Figure 7. The domain structure of SOCS proteins consists of a central SH2 domain and a SOCS box in the C-
terminus. 
 
The first member of SOCS family was denoted as CIS, for cytokine-inducible SH2-
containing protein (Yoshimura et al., 1995; Masuhara et al., 1997). CIS was cloned originally 
as an immediate early gene that was induced by IL-2, IL-3, and EPO (Matsumoto et al., 
1997). Forced expression of CIS could partially suppress IL-3- or EPO-induced proliferation 
as well as Stat5 activation (Yoshimura et al., 1995; Matsumoto et al., 1997). CIS acts as a 
negative feedback regulator of the Jak-Stat5 pathway. The negative effects of CIS on Stat5 
activity were confirmed by the phenotypes observed in CIS-transgenic mice (Matsumoto et 
al., 1999) (Table 4). CIS inhibits signaling by interacting with activated cytokine receptors. 
At the EPO receptor, CIS binds specifically to the phosphorylated tyrosine residue Tyr401, 
which is one of the major Stat5 binding sites (Gobert et al., 1996; Klingmuller et al., 1997; 
Matsumoto et al., 1997). A likely explanation for the inhibition of Stat5 activity would 
therefore be that Stat5 and CIS compete for binding to the same tyrosine residue at the EPO 
receptor. In addition, CIS has been shown to bind to the tyrosine phosphorylated IL-3 receptor 
(Yoshimura et al., 1995) and IL-2 receptor (Aman et al., 1999).  
SOCS-1 was identified both as a Jak2-binding protein and as an inhibitor of IL-6 
signaling (Endo et al., 1997; Naka et al., 1997; Starr et al., 1997). SOCS-1 has been shown to 
interact with all Jak kinases and inhibit signaling by IL-2, IL-3, IL-4, IL-6, GH, LIF, PRL, 
IFNγ, and EPO (Table 4). The inhibitory mechanism of SOCS-1 has been proposed to 
involve, in the context of Jak2, a direct interaction with the kinase activation loop, thereby 
resulting in decreased catalytic activity of Jak2 (Endo et al., 1997; Yasukawa et al., 1999). 
SOCS-1 is strongly induced by IL-2, can associate with IL-2 receptor, and potently inhibits 
IL-2-induced Stat5 function, all of which suggest a significant role for SOCS-1 in regulating 
T-cell immune responses (Sporri et al., 2001). 
SOCS-2 has been shown to interact with the GH receptor and to inhibit GH-mediated 
Stat5 signaling (Ram and Waxman, 1999) (Table 4). SOCS-2 also interacts with the IGF-1 
receptor (Dey et al., 1998). SOCS-2 appears to mediate its effects by interaction with the 
receptor tyrosines (Ram and Waxman, 1999). Knockout and other studies suggested an 
important role for SOCS-2 in the regulation of growth, possibly by modulating GH and IGF-1 
signaling (Greenhalgh et al., 2002).  
The expression of SOCS-3 can be induced by many cytokines, including IL-2, IL-3, 
and EPO (Endo et al., 1997; Naka et al., 1997; Cohney et al., 1999), and by GH, leptin and 
insulin (Adams et al., 1998; Bjorbaek et al., 1998; Emanuelli et al., 2000) (Table 4). Analyses 
of either SOCS-3 transgenic or SOCS-3-deficient mice indicated that SOCS-3 plays a critical 
role in negatively regulating fetal liver erythropoiesis (Marine et al., 1999).  Consistent with 
this, SOCS-3 transgenic mice die of anemia secondary to a block in Epo-Stat5 signaling 
(Marine et al., 1999). SOCS-3 inhibits also PRL-induced Stat5 activation (Helman et al., 
1998). In addition, expression of SOCS-3 is rapidly induced in T-cells in response to IL-2, 
and SOCS-3 can strongly inhibit IL-2-induced Stat5 phosphorylation (Cohney et al., 1999). 
Unlike other SOCS proteins, SOCS-3 is rapidly tyrosine phosphorylated after IL-2 
stimulation (Cohney et al., 1999). It has been suggested that the phosphorylated SOCS-3 can 
interact with RasGAP, and also that the phosphorylation can inhibit the SOCS-3-elongin C 
interaction and activate proteasome-mediated SOCS-3 degradation (Cacalano et al., 2001; 
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Haan et al., 2003). SOCS-3 appears to function by interacting with Jak1 and inhibiting Jak1 
activation (Cohney et al., 1999), but SOCS-3 also binds to Jak2 and activated cytokine 
receptors (Chen et al., 2000; Sasaki et al., 2000).  
 
NAME INDUCED BY ASSOCIATES 
WITH 
INHIBITS 
SIGNALING BY 
KNOCKOUT 
PHENOTYPES 
CIS IL-1–IL-3, IL-6, IL-12, 
IL-13, LIF, G-CSF, 
GM-CSF, TPO, IFNγ, 
GH, leptin, EPO, PRL, 
LPS, TSLP, CNTF 
EPOR, IL-3R, 
GHR, IL-2R, 
PKCθ 
IL-2, IL-3, PRL, 
EPO, IGF-1, GH 
No phenotype of null, but 
enhanced T-cell signaling in 
transgenic mice  
SOCS-1 IL-2, IL-3, IL-6, IL-13, 
EPO, GH, PRL, GM-
CSF, CNTF, 
thyrotropin 
Jak1, Jak2, Jak3, 
Grb2, Vav, 
FGFR, PYK2, 
GHR, c-Kit, 
Flt3, IGF-1R 
IL-2, IL-3, IL-4, 
IL-6, GH, PRL, 
EPO, LIF, IFN-γ, 
IFN-α, OSM, 
TSLP, TPO, IGF-1 
Perinatal lethality owing to 
unopposed IFNγ-induced 
liver degeneration 
SOCS-2 IL-1–IL-4, IL-6, G-
CSF, GM-CSF, EPO, 
IL-9, GH, PRL, IFNγ, 
CNTF, IL-10 
IGF-1R, PRLR, 
GHR 
GH, IL-6, LIF, 
IGF-1, PRL 
Gigantism owing to 
unopposed signalling by GH 
and IGF-1 
SOCS-3 IL-1–IL-4, IL-1β, IL-6, 
IL-7, IL-9-IL-13, M-
CSF, G-CSF, EPO, 
TPO, TNFα, LIF, GH, 
leptin, PRL, GM-CSF, 
LPS, insulin, CNTF, 
thyrotropin 
Jak1, Lck, 
FGFR, Pyk2, 
GHR, EPOR, 
leptin receptor, 
gp130, IGF-1R 
IL-2, IL-3, IL-4, 
IL-6, IL-9, IL-11, 
GH, PRL, EPO, 
LIF, IFN-γ, IFN-α, 
CNTF, leptin, 
OSM, IGF-1, 
insulin 
Embryonic lethality owing 
to multiple placental and 
hematopoietic defects 
SOCS-4 ? ? ? ? 
SOCS-5 ? ? IL-6 ? 
SOCS-6 ? IRS-1, IRS-4, 
p85 regulatory 
subunit of PI3K, 
InsR 
insulin Growth retardation owing to 
a requirement for SOCS-6 
in the proper regulation 
downstream of IRS 
SOCS-7 ? Ash, Nck, PLCγ ? ? 
 
Table 4.
 SOCS proteins in cytokine signaling, modified from Krebs and Hilton, 2001; Cooney, 2002; Levy and 
Darnell, 2002. 
 
 
2.1.5. Targeted degradation 
Ubiquitin-proteosome-dependent degradation plays an important role in the down-
regulation of cytokine signaling. Stat proteins typically exhibit long half-lives (Haspel et al., 
1996), but the stability of Stat1, Stat2 and Stat3 can be dramatically reduced by infection of 
the cells with certain negative-strand RNA viruses (Paramyxovirinae) (Didcock et al., 1999; 
Parisien et al., 2001; 2002; Ulane et al., 2003). Proteosome inhibitors have been shown to 
stabilize the tyrosine phosphorylated Stat5. In addition, the C-terminus of Stat5 has been 
found to promote degradation (Wang et al., 2000a), suggesting that also the stability of Stat5 
might be regulated by degradation. An adapter protein c-Cbl was recently found to negatively 
regulate GH-stimulated Stat5-mediated transcriptional activation (Goh et al., 2002). In line 
with this, other studies have also demonstrated that murine embryonic fibroblasts derived 
from c-Cbl-deficient mice exhibit significantly increased levels of Stat5 protein (Blesofsky et 
al., 2001). Interestingly, c-Cbl inhibition of GH-stimulated Stat5-mediated transcription was 
not mediated by interference with events leading up to DNA-binding, but c-Cbl 
overexpression resulted in increased ubiquitylation and proteosomal degradation of the 
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tyrosine phosphorylated Stat5. This negative regulation is dependent on the integrity of both 
the tyrosine kinase-binding domain and the RING finger domain of c-Cbl (Lill et al., 2000; 
Ota et al., 2000). The c-Cbl RING finger has intrinsic E3 ligase activity that can 
independently recruit ubiquitin-conjugating enzymes and direct ubiquitin transfer to 
substrates (Joazeiro et al., 1999; Levkowitz et al., 1999; Yokouchi et al., 1999).  
 
 
2.1.6. Stat inhibitor proteins 
The PIAS (protein inhibitor of activated Stats) family includes five members, PIAS1, 
PIAS3, PIASy, PIASxα, and PIASxβ (reviewed in Shuai, 2000). PIAS proteins share several 
structural elements, which are well conserved along all family members. It was recently 
predicted that PIAS proteins harbor a putative DNA-binding domain, the SAP (SAF-A, 
Acinus, PIAS) module, at their N-terminus (Kipp et al., 2000). In addition, PIAS3 has a 
putative RING finger-like domain and the C-terminus of PIAS3 contains an acidic region 
(Jimenez-Lara et al., 2002). This same C-terminal region of PIAS1 has been shown to be 
involved in the interaction with Stat1 and required for the inhibition of Stat1-dependent gene 
activation (Liao et al., 2000). PIAS proteins can bind to distinct classes of nuclear proteins 
and enhance or repress the transcriptional activities of structurally unrelated factors, such as 
steroid receptors and Stats (Chung et al., 1997; Liu et al., 1998; Moilanen et al., 1999; Tan et 
al., 2000). PIAS1 binds to activated Stat1 dimers, thereby blocking their ability to bind DNA 
(Liao et al., 2000). Analogously, PIAS3 blocks Stat3 DNA-binding activity and Stat3-
mediated gene activation (Chung et al., 1997). PIAS3 was recently shown to inhibit also Stat5 
(Rycyzyn and Clevenger, 2002). PIAS proteins were shown to function as SUMO-1 (small 
ubiquitin-related modifier 1) -tethering proteins and zinc finger-dependent E3 SUMO protein 
ligases, and these properties possibly explain their ability to modulate the activities of various 
transcription factors (Kotaja et al., 2002). Sumoylation has been shown to be involved in the 
regulation of subcellular localization, stability, and activity of a variety of proteins 
(Chauchereau et al., 2003). 
 
2.2. Nuclear translocation of Stat5 
In unstimulated cells, Stats predominantly localize to the cytoplasm. Upon 
stimulation, Stats translocate rapidly to the nucleus and induce gene expression. After 
termination of the signal, Stats translocate back to the cytoplasm. Like all molecules larger 
than ~60 kDa, Stats are transported across the nuclear pore complex (NPC) in an active 
bidirectional process that is energy- and activation-dependent (Doye and Hurt, 1997). 
Subsequent studies have determined that the hydrolysis of GTP by Ran, a Ras-like small 
GTPase, provides energy required for the IFNγ-dependent nuclear import of Stat1 (Sekimoto 
et al., 1996). Active nuclear import of proteins is directed by a short amino acid sequence 
called a nuclear localization signal (NLS). The NLS is recognized and bound by members of 
the nuclear receptor family proteins, called importins. Importin-α recognizes the NLS and 
then functions as an adapter by binding importin-β (Gorlich et al., 1994). Importin-β in turn 
interacts with NPC and mediates the transport of the cargo into the nucleus. The rapid ligand-
mediated nuclear import of Stats has been shown to be dependent on tyrosine phosphorylation 
but not on association with the cytoskeleton (Lillemeier et al., 2001). To date, no classical 
NLS has been detected in Stats. Studies have noted a potential role of the DNA-binding 
domain of Stat in nuclear accumulation and suggested that a cluster of basic residues in DNA-
binding domain may have an import function (Herrington et al., 1999; Melen et al., 2001). 
The identification of putative NLS elements in cytokine receptors and ligands led to the 
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speculation that Stats may translocate to the nucleus through association with other signaling 
components (Subramaniam et al., 2000).  
The presence of Stats in the nucleus is transient and during the subsequent period of 
signal decay they are re-exported back to the cytoplasm in preparation for the next round of 
signaling. Analogous to import, nuclear export is specified by nuclear export signals (NES) 
(Fornerod et al., 1997). The export receptor CRM1 interacts with the NES in a Ran-GTP-
dependent manner and transports the protein back to the cytoplasm (Fornerod et al., 1997). 
Recent studies on Stat1 have provided important insights into how this protein is exported 
from the nucleus (Begitt et al., 2000; McBride et al., 2000; Mowen and David, 2000). Stat1-
NES, which is a leucine-rich helical segment present in the coiled-coil domain, appears to be 
masked when the dimers are bound to DNA (Begitt et al., 2000). During the period of signal 
decay, Stat1 is dephosphorylated leading to its dissociation from DNA, after which the NES 
becomes accessible to the CRM1 export carrier. 
The nuclear sojourn time of Stat5 is about 6 min, as shown by Swameye and 
coworkers (Swameye et al., 2003). Extrapolating from studies of other Stats, it can be 
assumed that the tyrosine phosphorylation and dimer formation are prerequisite to the 
translocation of Stat5 homo- and heterodimers to the nuclear compartment (Heim et al., 1995; 
Sasse et al., 1997; Mowen and David, 1998; Herrington et al., 1999). Consistent with this 
model, tyrosine phosphorylation of Stat5A and Stat5B has been demonstrated to be critical for 
Stat5 DNA-binding and transcriptional activation (Gouilleux et al., 1994; Barahmand-Pour et 
al., 1998; Herrington et al., 1999). Although tyrosine phosphorylation and dimerization 
precede nuclear translocation, a study of PRL receptor mutants suggested that Stat5 tyrosine 
phosphorylation and nuclear translocation are separately regulated events (Ali, 1998). 
Another study suggested that the DNA-binding activity of Stat5 was required for the GH-
induced nuclear accumulation of Stat5 (Herrington et al., 1999). No bona fide nuclear import 
signal has been identified in Stat5 (Herrington et al., 1999), but the dimerization-induced 
unmasking of a cryptic import signal in Stats has been suggested (Milocco et al., 1999). The 
export mechanism from the nucleus for Stat5 is unknown, but probably it is similar to the 
mechanism presented for Stat1. 
 
2.3. Stat5 in transcriptional activation 
2.3.1. Interaction of Stat5 with other transcription factors and coregulators 
The transcriptional regulation of eukaryotic genes involves the specific and ordered 
interaction of a large number of proteins including enhancer/promoter-specific transcription 
factors, chromosomal remodeling complexes, and components of the basal transcriptional 
machinery (reviewed in Blackwood and Kadonaga, 1998; von Hippel, 1998). Gene regulation 
is therefore a highly coordinated effort, which helps to ensure that correct genes are expressed 
only under appropriate circumstances. The first evidence of an interaction between Stats and 
other transcription factors came from the copurification of IRF-9 with Stat1 and Stat2 in the 
ISGF-3 complex (Eilers et al., 1993). Subsequent studies of Stat-dependent promoters 
provided evidence for the interaction with other transcription factors. One group of Stat-
binding coactivators are histone acetyltransferases (HATs), especially CBP/p300 (Paulson et 
al., 1999), but Stats bind also with other coregulator proteins. The molecular mechanisms that 
underlie Stat5-mediated transcription are not fully understood, but these mechanisms involve 
interactions and cooperation with both sequence-specific transcription factors as well as with 
transcriptional coregulators. The proteins shown to interact with Stat5 include glucocorticoid 
receptor (GR), centrosomal P4.1-associated protein (CPAP) (Peng et al., 2002), N-Myc 
interactor (Nmi) (Zhu et al., 1999), Specificity protein (Sp)1 (Martino et al., 2001), Ying 
Yang-1 (YY1) (Bergad et al., 2000), and C/EBPβ (Wyszomierski and Rosen, 2001). Stat5 
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interacts also with negative regulators of transcription, such as nuclear receptor corepressor, 
silencing mediator for retinoic acid receptor and thyroid hormone receptor (SMRT) 
(Nakajima et al., 2001). 
 
2.3.1.1. Stat5 in transcriptional control in PRL signaling 
The main actions of PRL, a polypeptide hormone secreted mainly by the pituitary and 
also by peripheral tissues, are related to lactation and reproduction. The biological effects of 
PRL can, however, be subdivided into five broad categories: reproduction, osmoregulation, 
growth, integument, and synergism with steroids (reviewed in Bole-Feysot et al., 1998). The 
PRL actions result from the interaction of PRL with its receptor, which leads to the activation 
of a cascade of intracellular events (reviewed in Groner and Gouilleux, 1995; Hynes et al., 
1997). Although the Jak2-Stat5 cascade is probably the most important signaling pathway 
used by PRLR, other pathways are also involved. Binding of Stat5 to the gene promoter is 
necessary for the induction of the expression of β-casein, αs1-casein (Jolivet et al., 1996), 
whey acidic protein (Li and Rosen, 1995), and β-lactoglobulin milk proteins (Burdon et al., 
1994). The physiological function of Stat5 in PRL signaling is clearly demonstrated in the 
knockout models, where Stat5-null mice show a mammary phenotype similar to that of the 
PRLR-deficient mice, exhibiting impaired differentiation of lobuloalveolar units and inability 
to lactate (Liu et al., 1997; Ormandy et al., 1997a; 1997b; Teglund et al., 1998; Miyoshi et 
al., 2001).  
 
 
Figure 8.
 Model for the hormonal synergism between PRL and glucocorticoids in the induction of the β-casein 
gene. Stat5 is activated after PRL binding to its receptor. Dexamethasone (Dex) binds to GR in the cytoplasm. 
Stat5 dimer and GR-Dex form then a complex, which translocates into the nucleus, binds to the β-casein 
promoter, and initiates transcription. In contrast to the requirement for a specific Stat5-binding site at the β-
casein promoter, no functional GRE is necessary. The synergistic activation of transcription needs Stat5 
activation and the presence of the transactivation function in the GR.  Modified from Groner, 2002. 
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The hormonal synergism between PRL and glucocorticoids in the induction of the β-
casein gene has been investigated in molecular detail (Doppler et al., 1989; 1990;  1995; 
Lechner et al., 1997b) (Figure 8). When glucocorticoid hormones are taken up into cells, they 
bind intracellularly to the latent form of the GR. Upon ligand binding, GR, which otherwise 
resides in the cytoplasm, translocates to the nucleus where it binds to palindromic 
glucocorticoid response elements (GREs) in the promoters of target genes (Beato et al., 1995; 
Bamberger et al., 1996). GR can also interact with GRE half-sites, a DNA-interaction that can 
be stabilized by other transacting factors binding to adjacent sequences. A single Stat5-
binding site in the promoter region of a target gene is sufficient to confer the functional 
interaction, but the synergism is enhanced when multimerized Stat5-binding sites are present. 
The synergistic activation of transcription needs Stat5 activation and the presence of the 
transactivation function in the GR. In contrast to the requirement for a specific Stat5-binding 
site, no functional GRE is necessary (Stoecklin et al., 1996; 1997; 1999). Recently, Doppler 
and coworkers reported that GR enhances Stat5 activity in the absence of a functional DNA-
binding domain and GR-binding sites only when high expression levels are used, suggesting 
that the mode of action of the GR may depend on the concentration of the GR (Doppler et al., 
2001). The regulatory factors governing milk protein gene expression are not limited to Stat5 
and the GR, but include additional signal-regulated components (Figures 9 and 10). These 
include C/EBPs, NF1, YY1 (Stocklin et al., 1996; 1997; Robinson et al., 1998; Wyszomierski 
and Rosen, 2001) and other transcription factors characterized in less detail (Altiok and 
Groner, 1994; Rosen et al., 1998; 1999). In addition, Stat5 associates with CBP/p300 at the β-
casein promoter (Pfitzner et al., 1998). 
 
 
 
Figure 9. Diagrammatic representation of the rat β-casein promoter including the response elements for critical 
transcription factors, adapted from Rosen et al., 1999. 
 
     
 
 
 
Figure 10.
 Model for protein interactions at 
the β-casein promoter involved in chromatin 
remodeling. In the active state, interactions 
between Stat5, C/EBPβ, and GR create a 
stable activation complex. The three proteins 
together recruit CBP/p300 to the β-casein 
promoter, causing histone acetylation and a
high level of transcriptional activation. Also 
the proteins involved in the repressed state 
have been characterized. In the repressed 
state, the LIP (liver-enriched inhibitory 
protein), which is an inhibitory form of 
C/EBPβ, may tie YY1 to the weak YY1-
binding site at the β-casein promoter. YY1 
may then recruit histone deacetylases 
(HDACs), resulting in histone deacetylation 
and repression of transcription. Adapted from 
Rosen et al., 1999. 
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2.3.2. Genes regulated by Stat5  
In the nucleus, dimerized Stat5 interacts directly with specific DNA elements through 
a centrally located DNA-binding domain. Studies on Stat5-responsive gene promoters have 
shown that Stat5 recognizes and binds to canonical GAS sites with the general sequence 
TTCNNNGA (reviewed in Ihle, 1996). Because multiple Stats retain ability to bind the same 
highly conserved sequences, there is significant overlap in the DNA site recognition between 
Stat5, Stat1, and Stat3 (reviewed in Decker et al., 1997; Leonard and O'Shea, 1998). The 
functions of individual Stat proteins are often redundant due to overlapping specificities for 
common promoter elements. Stat dimers can undergo tandem linkage through their N-
terminal domains when bound to closely located GAS sites (Xu et al., 1996a; Verdier et al., 
1998). Stabilization achieved by these complexes can thus lead to transcriptional activation 
from coupled GAS sites that individually are too weak to drive transcription (Verdier et al., 
1998; John et al., 1999). Tandem Stat5-response elements have been found in the promoter of 
the IL-2 receptor α (Verdier et al., 1998; John et al., 1999), and also in the promoters of the 
CIS and the Serine protease 2.1 (Spi2.1) (Bergad et al., 1995; Minamoto et al., 1997).  
Stat5 regulates immediate early cytokine-inducible genes (Table 4). These targets 
include pim-1, osm, and cis in hematopoietic cells (Lilly et al., 1992; Yoshimura and Arai, 
1996; Matsumoto et al., 1997), and genes responsive to pulsatile action of GH in the male rat 
liver (Gebert et al., 1997; Udy et al., 1997). In fact, many of the genes, which respond to 
Stat5 and include defined Stat response elements, are primarily associated with mammary 
gland milk production and the cell cycle progression of hematopoietic cells. The Stat5-
dependent mechanisms involved in protection from apoptosis, growth factor-independent 
proliferation, and transformation are not known, but the possible role of genes 
transcriptionally regulated by Stat5, such as a1 (Lin et al., 1996), bcl-xL (Socolovsky et al., 
1999), pim-1 (Lilly et al., 1992), and osm (Yoshimura and Arai, 1996) should be considered. 
A1 and Bcl-xL belong to the Bcl-2 family of proteins that protect cells from apoptosis 
(Motoyama et al., 1995; Hamasaki et al., 1998). In addition, the human homologue of A1 
(Bfl-1) cooperates with the E1A oncogene in transformation (D'Sa-Eipper et al., 1996). 
Activation of pim-1 gene correlates with mitogenesis and growth factor-independent survival 
(Lilly et al., 1992; Mochizuki et al., 1999) and OSM is able to stimulate growth of various 
cells (Gomez-Lechon, 1999).  
 
 
Table 4.
 Examples of Stat5-induced genes, modified from Grimley et al., 1999. 
 
2.3.2.1. Pim-1 
The cytoplasmic serine/threonine kinase Pim-1 acts as a survival factor to inhibit 
apoptosis in myeloid cells deprived of cytokines (Lilly and Kraft, 1997). Pim kinase is a labile 
protein whose expression is especially high in hematopoietic and germ cells. A single Pim-1 
protein of 33 kDa exists in humans, while mice have 33 and 44 kDa forms. The latter results 
from an alternate translational start site missing in the human gene (Saris et al., 1991). 
Approximately equal amounts of the two murine forms are expressed in hematopoietic cells 
(Saris et al., 1991; Lilly and Kraft, 1997). The cloning of the highly homologous pim-2 (van 
der Lugt et al., 1995) and pim-3 genes (Konietzko et al., 1999) suggested that there is a 
STAT5-INDUCED GENES 
β-casein, β-lactoglobulin, bcl-xL, bile acid cotransporter, carboxyl ester lipase, cyclin D1, cyp19, 
cyp3a10, insulin, IRF-1, osm, p21waf1/Cip1, pim-1, α2-macroglobulin  
STAT5-REGULATED GENES WITH TANDEM GAS SITES 
il-2 receptor α-chain, spi2.1 and spi2.2, cis, fc receptor γ-chain 
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family of Pim kinases. The expression of Pim-1 is induced by hematopoietic growth factors 
including IL-2, IL-3, GM-CSF, EPO, but is also induced by PRL (Dautry et al., 1988; Lilly et 
al., 1992; Miura et al., 1994; Buckley et al., 1995). 
The proto-oncogene pim-1 was originally identified as a preferential integration site of 
Moloney murine leukemia virus, which induces T-lymphomas in mice (Cuypers et al., 1984). 
Oncogenity of Pim-1 has been characterized in both transgenic and retroviral models (Selten 
et al., 1986; Breuer et al., 1989). Accordingly, overexpression of Pim-1 protein is seen in 
erythroleukemias (Dreyfus et al., 1990), various human leukemias (Amson et al., 1989), and 
in B-cell lymphomas (Verbeek et al., 1991). By itself, Pim-1 has low oncogenic potential, but 
it strongly cooperates with c-Myc, L-Myc, N-Myc, Bcl-2, and Gfi-1 in T-cell 
lymphomagenesis (van Lohuizen et al., 1989; Moroy et al., 1991; Schmidt et al., 1998; Wang 
et al., 2001b). Pim-1 has been shown to be involved in the IL-3 signal transduction pathway, 
in cell cycle regulation and proliferation, and in apoptosis and cell survival (reviewed in 
Wang et al., 2001b).  
Some substrates for Pim-1 have been identified; p100 (originally identified as a 
coactivator for EBNA-2) (Leverson et al., 1998), a cell cycle phosphatase cdc25A 
(Mochizuki et al., 1999), heterochromatin protein 1 (HP1) (Koike et al., 2000), Pim-1-
associated protein 1 (PAP1) (Maita et al., 2000), a tyrosine phosphatase PTP-U2S (Wang et 
al., 2001a), NFATc1 transcription factor (Rainio et al., 2002), tumor necrosis factor receptor-
associated factor 4-associated factor 2/sorting nexin 6 (TFAF2/SNX6) (Ishibashi et al., 2001), 
nuclear mitotic apparatus protein (NuMA) (Bhattacharya et al., 2002), and a cyclin-dependent 
kinase inhibitor p21 (Wang et al., 2002). Recently, Pim-1 and Pim-2 were shown to regulate 
the stability of SOCS-1 by phosphorylating it (Chen et al., 2002).  
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AIMS OF THE PRESENT STUDY 
 
Stat5 mediates signals for a variety of cytokines and growth factors. Stat5 activation is 
often an integral component of redundant signal cascades involving complex cross-talk. 
However, relatively little is known about how Stat5 activation is regulated in the cell. The 
transcriptional coregulators that interact with Stat5 and function together with Stat5 to 
regulate gene transcription are still largely unknown. Also the exact mechanisms by which 
Stat5 signal is down-regulated after specific stimulation have remained somewhat elusive. 
 
The detailed aims of this thesis study were: 
 
1) To study the activation of Jak kinases and Stat factors upon PDGF stimulation.  
 
2) To characterize coregulators for the Stat5-mediated transcription. 
 
3) To study the effect of a Stat5 target gene Pim-1 on Stat5 activity. 
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MATERIALS AND METHODS 
1. Cell lines and stimulations 
Cell lines 
 
Name and description Used in Culture medium (all mammalian cell culture 
medias include glutamin, penicillin, and 
streptomycin)
 
293T, Human kidney epithelial cells, 
ATCC
  
II, III D-MEM+10%FBS 
COS-7, African green monkey kidney 
epithelial cells, SV40 transformed, 
ATCC
  
I, II, III, 
IV 
D-MEM+10%FBS 
Swiss 3T3, mouse fibroblasts, ATCC  I D-MEM+10%FBS 
NIH 3T3, normal mouse fibroblasts, 
ATCC  
I D-MEM+10%NBCS 
Src-/- and Fyn-/- mouse fibroblasts, 
derived from Src-/- and Fyn-/- mice 
(Soriano et al., 1991; Stein et al., 1992), 
were gift from Dr. P. Soriano. 
II D-MEM+10%NBCS 
32D, ATCC  I RPMI 1640+10%FBS + 2.5 ng/ml mIL-3 
PAE cells expressing  
wt PDGF α-R (Eriksson et al., 
1992b), wt β-R, or β-R mutants 
Y579F, Y581F (Mori et al., 1993)   
I, II Ham’s F-12 medium+10%FBS 
PAE cells expressing PDGF β-R 
mutants K634A (Sorkin et al., 1991); 
Y716F (Arvidsson et al., 1994);  
Y740/751F (Wennstrom et al., 1994); 
Y1009/1021F (Ronnstrand et al., 
1992);
  
Y771F, Y775F, Y778F (Ruusala et 
al., 1998).
 
I Ham’s F-12 medium+10%FBS 
Sf-9, insect cells (Smith et al., 1985) II Sf900 medium (Invitrogen)+10%FBS  
FDCP1/neo and FDCP1/Pim, (Lilly 
and Kraft, 1997)
 
IV RPMI 1640+10%FBS + 2ng/ml mIL-3 or 
10% WEHI medium 
HC11 (Ball et al., 1988) III, IV RPMI 1640+10%FBS+5µg/ml 
insulin+10ng/ml EGF + 50µg/ml 
Gentamycin 
HC11-pCIneo, HC11-p100 III RPMI 1640+10%FBS+5µg/ml 
insulin+10ng/ml EGF +geneticin (G418, 
Life Technologies) 
HeLa, ATCC  IV MEM+10%FBS 
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Cytokines, growth factors and hormones 
 
Cytokine, growth factor, hormone Used in Company 
PDGF-AA I Upstate Biotechnology 
PDGF-BB I, II Upstate Biotechnology 
Prolactin (PRL) III, IV Sigma-Aldrich  
Dexamethasone (Dex) III Sigma-Aldrich 
Epidermal growth factor (EGF) III, IV Sigma-Aldrich 
Insulin III, IV Sigma-Aldrich 
Interleukin 3 (IL-3) IV Peprotech 
Erythropoietin (EPO) IV Eprex; Janssen-Cilag 
 
Stimulations 
Before stimulation COS-7 and 293T cells were starved overnight without serum, 
followed by stimulation with 50 ng/ml PDGF-BB for 10 min at 37 ºC. All fibroblasts were 
stimulated with 100 ng/ml PDGF-BB for 10 min at 37 ºC after overnight starvation in 0.2% 
NBCS. PAE cells were stimulated with 100 ng/ml PDGF-BB for 10 min at 37 ºC.  32D cells 
were starved without IL-3 and serum overnight and stimulated with 10 ng/ml mIL-3 for 15 
min. Prior to treatment with lactogenic hormones, confluent HC11 cells were starved for 48 h 
in medium lacking EGF, but containing 5 µg/ml insulin and 2% FBS. Stimulation was done in 
starvation media with 5 µg/ml PRL and 100 nM Dex for 15 min - 20 h.  FDCP cells were 
starved for 6 h, after which they were stimulated with 10 ng/ml mIL-3 for 16 h. HeLa cells 
transfected with EPO receptor were starved without serum and stimulated with 10 U/ml EPO 
for 6 h. 
2. Baculoviruses 
Virus Used in Reference/Source 
βRic II (Hansen et al., 1996) 
Jak1 II Dr. J. Ihle (Quelle et al., 1995) 
c-Src II Dr. D. O. Morgan 
Stat5A II Dr. T. Wood 
3. Methods used 
Method Used and described in 
Cell lysis I, II, III, IV 
Electrophoretic mobility shift assay (EMSA) I, II, III, IV 
GST pulldown III, IV 
Immunoprecipitation I, II, III, IV 
In vitro kinase assay  I, II, IV 
Luciferase assay III, IV 
Nonradioactive kinase assay II 
Peptide binding/peptide inhibition I 
PRE binding  I 
Transfection  I, II, III, IV 
Western blotting I, II, III, IV 
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4. DNA constructs 
DNA constructs  Used in Reference/Source 
pSV7d I, II  (Truett et al., 1985) 
PDGF β-R-pSV7d I, II (Claesson-Welsh et al., 1988)  
PDGF β-R-pCIneo II II 
PDGF β-R mutants Tyr579Phe 
(Y579F)- and Y581F-pSV7d 
I (Mori et al., 1993) 
PDGF β-R mutants Y579F-pCIneo 
and Y581F-pCIneo   
II 
 
II 
 
pCIneo II, III, IV Promega 
Jak1    II (Silvennoinen et al., 1993a) 
c-Src II (Silvennoinen et al., 1993b) and II 
Src-KN (Lys297Met) II Dr. D. O. Morgan 
sheep Stat5A (MGF) I, II Dr. B. Groner (Wakao et al., 1994)
  
Mouse Stat5A II, III, IV Dr. T. Wood  
SH2 mutant (Arg618Leu) of mouse 
Stat5A  
II, III Dr. T. Wood 
pSpi-luc2 III, IV Dr. T. Wood  (Sliva et al., 1994)  
Jak1-KN (mutation Lys835Glu) II (Silvennoinen et al., 1993a) and II 
Jak2-KN-HA (mutation Lys882Glu) II (Saharinen et al., 1997) and II 
pSG5-p100-Flag III, IV (Yang et al., 2002) 
pSG5-SN-Flag (amino acids 1-639) III (Yang et al., 2002) 
pSG5-TD-Flag (amino acids 640-885) III (Yang et al., 2002) 
SN-GST and TD-GST III (Yang et al., 2002) 
pGEX-4T-1 II, III, IV Amersham Pharmacia Biotech 
Stat5A-TAD-GST III, IV III 
pZZ1 III (Gouilleux et al., 1994) 
C/EBPβ luciferase reporter III (Pesu et al., 2000)  
NF-κB luciferase reporter  III (Saksela and Baltimore, 1993) 
CBP-HA III (Chrivia et al., 1993) 
pLTR-Pim-1, pLTR-Pim-
1(Lys67Met), pECFP-Pim-1 
IV (Rainio et al., 2002) 
Pim-GST / Pim(Lys67Met)-GST IV (Rainio et al., 2002) 
pCMV-Pim-1 IV (Leverson et al., 1998) 
pRLTK III, IV Promega 
pSV-ß-galactosidase IV Promega 
pME18S-SOCS-1,-2, and -3 IV Dr. D. J. Hilton 
SOCS-3-pCIneo IV Dr. J. A. Johnston 
SOCS-3-GST IV Dr. J. A. Johnston  
pLTRpoly IV (Makela et al., 1992) 
pEGFP-C1  IV Clontech Laboratories 
NFAT-LUC  IV Dr. G. R. Crabtree  
AP-1-LUC IV Dr. G. R. Crabtree 
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5. Antibodies 
Antibodies Used in Company, provider or reference 
monoclonal anti-phosphotyrosine (clone 
4G10) 
II, III, IV Upstate Biotechnology 
monoclonal anti-phosphotyrosine (PY20) I, II Transduction Laboratories 
monoclonal anti-Jak1 II Transduction Laboratories 
polyclonal anti-PDGF β-R II Upstate Biotechnology 
monoclonal anti-Stat5A II, III, IV Zymed Laboratories  
monoclonal anti-Flag M2 III, IV Sigma-Chemical 
polyclonal anti-Stat5B (C-17x) I, III Santa Cruz Biotechnology 
polyclonal c-Src antibody II Santa Cruz Biotechnology 
monoclonal anti-HA antibody (clone 
16B12) 
II, III Berkeley Antibody Company 
monoclonal anti-v-Src (Ab-1) II Oncogene Research Products 
rabbit antiserum against Jak1  I (Silvennoinen et al., 1993a) 
rabbit antiserum against Jak2 I (Silvennoinen et al., 1993a) 
rabbit antiserum against Tyk2 I Santa Cruz Biotechnology  
rabbit antiserum against Stat5 I Santa Cruz Biotechnology  
monoclonal anti-Stat1 antibody I Transduction Laboratories 
monoclonal anti-Stat3 antibody I Transduction Laboratories 
monoclonal anti-Stat4 antibody I Transduction Laboratories 
monoclonal anti-Stat5 antibody I Transduction Laboratories 
monoclonal anti-Stat6 antibody I Transduction Laboratories 
monoclonal anti-Jak1 antibody I, II Transduction Laboratories 
rabbit antiserum against PDGFR-3  I 
rabbit antiserum against PDGFR-HL2 I 
(Claesson-Welsh et al., 1988; 
Welsh et al., 1990) 
rabbit antiserum PDGFR-7 I (Eriksson et al., 1992a) 
rabbit antiserum PDGFR-4 I Dr. S. Courtneidge 
rabbit antiserum against Stat3 I Dr. X. Cao 
rabbit antiserum against green fluorescent 
protein (GFP)  
IV Clontech Laboratories 
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RESULTS 
1. Activation of Stat family members in PDGF signaling (I, II) 
1.1. PDGF-induced activation of Stat family members (I) 
At the beginning of this study, quite a wealth of knowledge about cytokine receptors 
activating Jak kinases and Stat factors existed. However, the activation patterns and the 
mechanisms by which these proteins are activated by growth factor receptors were largely 
unknown. Upon stimulation, PDGF receptors were known to activate a number of different 
signaling molecules (reviewed in Heldin, 1997; 1998), and we got interested in studying 
whether Stat family members are also activated. For this purpose, we examined the 
phosphorylation of Stat1 in Swiss 3T3 cells expressing high levels of both PDGF α-R and 
PDGF β-R. Stimulation led to increased Stat1 tyrosine phosphorylation, which was at its 
maximum after 10 min stimulation (I, Fig. 1A). Subsequently, also Stat3 and Stat5 were 
found to be tyrosine phosphorylated (I, Fig. 1B and C), while no phosphorylation of Stat2, 
Stat4, or Stat6 was detected. In addition, both PDGF α- and β-Rs appeared to induce DNA-
binding activity of Stat1, Stat3 and Stat5, as shown in electrophoretic gel-mobility shift assay 
(EMSA) (I, Fig. 2). To compare the strength of PDGF-induced Stat activation to the 
activation induced by a cytokine, we analyzed nuclear extracts from PDGF-stimulated Swiss 
3T3 cells and from IL-3-stimulated 32D cells by EMSA. It appeared that PDGF-BB and IL-3 
similarly stimulated the DNA-binding activity of Stat5 (I, Fig. 3). 
 
1.2. Tyrosine phosphorylation of Stat5 requires kinase activity of the PDGF β-R 
and involves certain receptor tyrosines (I, II) 
Our next step was to determine the required elements of the PDGFR system for Stat 
activation. We selected Stat5 to further studies, because it was strongly activated by PDGF. 
We first investigated whether the kinase domain of the PDGF β-R was required for tyrosine 
phosphorylation of Stat5. For this purpose, we compared the activation of Stat5 in porcine 
aortic endothelial (PAE) cells expressing wild-type PDGF β-R with cells expressing a mutant 
receptor with amino acid substitution in the catalytic domain (Lys634Ala) that inactivates the 
catalytic activity of the receptor (Sorkin et al., 1991). Tyrosine phosphorylation of Stat5 was 
found to be dependent on the catalytic activity of the PDGF β-R (I, Fig. 4).  
In cytokine receptor signaling the Stats are recruited through their SH2 domain to the 
tyrosine phosphorylated receptor complex and this association is a prerequisite for the C-
terminal tyrosine phosphorylation. We wanted to know whether the tyrosine phosphorylation 
of Stat5 was dependent on association with any of the phosphorylation sites in the PDGF β-R. 
For this purpose, we used PAE cell lines stably expressing different PDGF β-R mutants. In 
cells expressing receptor mutant Tyr581Phe (Y581F), tyrosine phosphorylation of Stat5 was 
found to be considerably decreased (I, Fig. 5 and Table 1). There was also a decrease in 
tyrosine phosphorylation of Stat5 in the cells expressing Y579F or Y775F mutant β-Rs, 
whereas other receptor mutants showed tyrosine phosphorylation close to that of the wild-type 
receptor. Also the DNA-binding activity of Stat5 in PAE cells expressing Y581F, Y579F, and 
Y775F receptor mutants was reduced (I, Fig. 6). Consistent with the results obtained in PAE 
cells with stably transfected receptor mutants, PDGF β-R mutants failed to induce the 
phosphorylation of Stat5 also in COS-7 cells (II, Fig. 3A). However, the Y579F and Y581F 
mutations did not affect autokinase activity of the PDGF β-R, and both mutant receptors were 
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also able to phosphorylate Stat5 peptide as efficiently as the wild-type receptor (II, Fig. 3B). 
Thus, the defect in the activation of Stat5 is not due to the reduced catalytic activity of the 
mutated receptors towards Stat5. Assays with phosphorylated or unphosphorylated peptides 
corresponding to Y579F, Y581F or Y775F and their surrounding amino acid residues, 
revealed that Stat5 bound efficiently to peptides containing phosphorylated Y579F, Y581F or 
Y775F, but very weakly to the corresponding unphosphorylated peptides (I, Fig. 7). In 
addition, peptides with phosphorylated Y579 or Y581 competed efficiently with binding of 
Stat5 to all three peptides. Moreover, a peptide with phosphorylated Y775 competed well 
with the binding of Stat5 to the same immobilized peptide, but less efficiently with the 
binding to immobilized peptides containing phosphorylated Y579 or Y581. This in vitro 
binding data is consistent with a direct association between Stat5 and phosphorylated Y579, 
Y581 and Y775. In addition, we found that only wild-type Stat5, but not the SH2 mutant 
(Arg618Leu) form, became tyrosine phosphorylated upon PDGF stimulation (II, Fig. 4). 
These results indicated that PDGF-induced activation of Stat5 requires the SH2 domain of 
Stat5 and that PDGF β-R mutations interfere with the association of Stat5 to the receptor. 
 
2. PDGF β-R, Jak1 and c-Src in the activation of Stat5 (I, II) 
2.1. Interaction between the PDGFRs and Jaks (I) 
It was now evident that PDGF receptors activated Stats. The activation mechanism 
was, however, unknown. In cytokine signaling, Jak kinases are thought to be the predominant 
activators for Stats and their activation was therefore interesting also in our PDGF-related 
studies. We first studied the interaction between Jak proteins and the PDGF receptors. PDGF 
β-R was brought down from ligand-stimulated cells by an antiserum against Jak1, and to a 
considerably lesser extent by antisera against Jak2 or Tyk2 (I, Figs. 8A and 8B). Jak1 
coprecipitated to some extent also with the unstimulated receptor, whereas stimulation 
resulted in an increased association between Jak1 and the receptor (I, Fig. 9A). We also 
investigated the ability of the PDGF α-R to associate with different Jaks. PDGF α-R was seen 
in Jak1 immunoprecipitations after stimulation, but not after immunoprecipitation with 
antisera against Jak2 or Tyk2 (data not shown). We also saw an induction in the level of 
tyrosine phosphorylated Jak1 after stimulation (I, Fig. 9B). To estimate the kinase activity of 
Jak1 in response to PDGF, the immunoprecipitated Jak1 was assayed in in vitro kinase assay 
with a substrate peptide corresponding to the Jak2 phosphorylation site (Silvennoinen et al., 
1993c; Feng et al., 1997). PDGF clearly induced the kinase activity of Jak1 as compared to 
unstimulated cells (I, Fig. 9C). Taken together, these results demonstrate that the PDGF β-
receptor associates with Jak1 and to a lesser extent with Jak2 and Tyk2, whereas the activated 
PDGF α-R associates only weakly with Jak1 and not detectable with Jak2 and Tyk2. The 
association between Jak1 and the receptor, as well as the tyrosine phosphorylation and kinase 
activity of Jak1, were increased by PDGF. 
2.2. Activation of Stat5 by PDGF β-R, Jak1 and c-Src (II) 
Jak kinases are activated upon PDGF stimulation, but so are Src family kinases and 
the PDGFR itself. To gain insight into the individual roles of different PDGF-induced 
tyrosine kinases in the activation of Stat5, we analyzed the abilities of PDGF β-R, c-Src, and 
Jak1 to activate Stat5 in insect and mammalian cells. Jak1 was chosen for these studies, since 
it appeared in our studies to be the predominantly activated Jak kinase in PDGF β-R 
signaling. Also Src kinases were interesting, since their activation was shown to lead to Stat5 
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activation in several occasions (Yu et al., 1995; Cao et al., 1996; Chaturvedi et al., 1997; 
1998). Furthermore, Src kinases c-Src, Fyn and c-Yes were known to bind directly to the 
PDGF β-R autophosphorylation sites Y579 and Y581 (Anderson et al., 1990; Twamley-Stein 
et al., 1993), which were found to be critical for the activation of Stat5 in our studies. In 
addition, there were reports about different RTKs to be able to activate Stat proteins directly 
(Quelle et al., 1995; Park et al., 1996; Chen et al., 1997; Choudhury et al., 1998). 
Our results in insect cells showed that Stat5 became efficiently phoshorylated in cells 
expressing the intracellular part of the PDGF β-R (βRic) and to a lesser extent in Jak1 
expressing cells (II, Fig. 1A). Low levels of tyrosine phosphorylation of Stat5 could also be 
detected in c-Src expressing cells. The DNA-binding activity of Stat5 was analyzed in EMSA, 
and again the receptor intracellular region and Jak1 clearly induced the DNA-binding activity 
of Stat5 (II, Fig. 1B). In contrast, the DNA-binding activity of Stat5 was only weakly induced 
by c-Src. The kinases were found to be tyrosine phosphorylated at similar levels (II, Fig. 1C). 
However, tyrosine phosphorylation does not always correlate with the kinase activity, and in 
autokinase assays c-Src showed high kinase activity (II, Fig. 1D). In line with the results from 
insect cells, PDGF β-R, as well as Jak1, induced DNA-binding activity of Stat5 when 
coexpressed in 293T cells (II, Fig. 2A). c-Src, which was expressed in mammalian cells, 
showed a strong autokinase activity (II, Fig. 2B), but was not able to induce the DNA-binding 
activity of Stat5. The results with immunoprecipitated kinases subjected to in vitro peptide 
kinase assays with Stat5 using peptide containing Y694 as a substrate, showed that PDGF β-
R, as well as c-Src, were capable to phosphorylate the Stat5 peptide (II, Fig. 2B). However, 
taken into account the high autokinase activity of c-Src, the Y694 site did not appear to be an 
optimal substrate for c-Src. In several autokinase assay experiments Jak1 phosphorylated the 
peptide at similar level as PDGF β-R. 
The efficient phosphorylation of Stat5 by βRic in insect cells suggested that PDGF β-
R might be the kinase phosphorylating Stat5 in PDGF signaling. However, we wanted to 
confirm that the PDGF β-R-induced activation of Stat5 was mediated by the receptor and not 
by other receptor-activated kinases. Therefore, we analyzed the ability of βRic to directly 
phosphorylate Stat5 in vitro in a nonradioactive phosphorylation assay. Stat5 was 
phosphorylated only in the presence of βRic (II, Fig. 1E). In autokinase assay from 
immunoprecipitated βRic (II, Fig. 1F) we could not detect other phosphorylated proteins even 
after longer exposures, suggesting that the phosphorylation of Stat5 was mediated directly by 
PDGF β-R and not by coimmunoprecipitating kinases.  
2.3. The effect of kinase negative c-Src, Jak1 and Jak2 on the PDGF-induced 
activation of Stat5 (II) 
According to our results, it seemed that the PDGF β-R phosphorylated Stat5 directly. 
To explore the possibility that Jak or Src kinases participate in the activation of Stat5 
indirectly, we used the catalytically inactive mutants of c-Src, Jak1 and Jak2 kinases. These 
mutants, when coexpressed, compete with and inhibit wild type kinases and may also 
overcome the redundancy of the different Src and Jak family members (Briscoe et al., 1996; 
Kohlhuber et al., 1997). The effects of Src-KN (Lys297Met), Jak1-KN (Lys835Glu), and 
Jak2-KN (Lys882Glu) on the PDGF-induced tyrosine phosphorylation and DNA-binding 
activity of Stat5 were analyzed. Coexpression of Jak1-KN or Jak2-KN had no inhibitory 
effect on the PDGF-induced phosphorylation or DNA-binding of Stat5, while Src-KN 
inhibited the PDGF-induced activation of Stat5 (II, Figs. 5A and 5B). Interestingly, c-Src 
inhibited the activation to the same degree as the Src-KN, while no inhibition was observed in 
cells cotransfected with wild-type Jak1 (II, Fig. 5C). The observed inhibition by Src-KN 
could either result from abrogation of Src kinase activity or from competition between Src 
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and Stat5 for binding to the receptor. According to our results, it was quite obvious that the 
inhibition was due to the competition between Src and Stat5. We also utilized Src-/- and Fyn-
/-
 cells to further analyze if the PDGF-induced activation of Stat5 was dependent on either 
one of these PDGF β-R-activated Src kinases. However, tyrosine phosphorylation of Stat5 
occurred at similar levels and kinetics in Src-/- and Fyn-/- cells as in normal control 
fibroblasts, indicating that both c-Src and Fyn are dispensable for the PDGF-induced 
activation of Stat5 (II, Fig. 6).  
These results indicate that the catalytic activity of c-Src, Jak1 or Jak2 is not required 
for the PDGF-induced activation of Stat5. Together with the results from receptor mutant 
experiments, the results further suggest that Stat5 and c-Src compete for the same receptor 
binding sites, which results in reduced phosphorylation of Stat5. 
 
 
3. p100 functions as a coactivator for Stat5 in HC11 cells (III) 
PRL and glucocorticoid hormones act synergistically to induce the β-casein gene 
expression in mammary epithelial cells. The known regulatory factors governing milk protein 
gene expression include Stat5, GR, C/EBPs, NF-1, YY1 (reviewed in Rosen et al., 1998), and 
CBP/p300 (Pfitzner et al., 1998). Of these factors, Stat5 has been shown to directly interact 
with GR (Stocklin et al., 1996), C/EBP (Wyszomierski and Rosen, 2001), CBP/p300 (Pfitzner 
et al., 1998), and YY1 (Bergad et al., 2000). These interactions might complement regulatory 
mechanisms, which are based on the composite structure of promoters with respect to 
transcription factor binding sites. Additionally, they bring into proximity the binding sites for 
Stat5 and other transcription factors possibly to promote their functional interactions.  
The p100 coactivator was first identified in HeLa cells by its ability to interact with an 
Epstein-Barr virus-encoded transcription factor, Epstein-Barr virus nuclear antigen-2 (EBNA-
2), and a component of the transcription initiation complex, transcription factor IIE (Tong et 
al., 1995). Coactivation was further demonstrated by transfection of p100 into B-
lymphoblasts, where it enhanced the transactivational activity of EBNA-2. Analysis of the 
p100 sequence revealed four repeated domains that have similarity to staphylococcal 
nucleases (SN-like domains) (Callebaut and Mornon, 1997; Ponting, 1997a). The similarity 
suggested that p100 shares a common protein fold with staphylococcal nucleases, although 
key residues required for nuclease activity were absent. A domain near the C-terminus, a TD 
domain, which is also found in multiple copies in the Tudor protein of Drosophila (reviewed 
in Ponting, 1997b) was also identified. Interestingly, when proteins that play a role in 
controling lactation were sought, one of these proteins was identified as p100 (Broadhurst and 
Wheeler, 2001). In addition, the p100 protein was earlier shown to be present in endoplasmic 
reticulum and in lipid droplets of milk-secreting cells, and to be localised to both the 
membrane/organelle fraction and the nuclei of mammary epithelial cells (Keenan et al., 
2000). Interestingly, the p100 protein levels were increased in response to lactogenic stimuli 
in mammary cells. However, the function of this coactivator in mammary epithelial cells 
remained to be demonstrated. 
3.1. p100 enhances the transcriptional activity of Stat5 in HC11 cells  
At the beginning of this study, we became interested in finding proteins interacting 
with Stat5. At the same time in our laboratory, Dr. Yang Yie found that a coactivator protein 
p100 interacted with Stat6 and functioned as a coactivator in Stat6-dependent transcriptional 
regulation. When, in addition, p100 protein was found to be abundant in the nuclei of 
mammary epithelial cells (Broadhurst and Wheeler, 2001), and the protein levels were shown 
 41 
to be increased in response to lactogenic hormones during lactation and to correlate well with 
the induction of the β-casein gene expression, we started to consider whether p100 is involved 
in the PRL-induced transcriptional activation of Stat5. Mouse HC11 mammary epithelial cells 
were used for most of our studies, since they had earlier been used to characterize molecular 
events involved in the regulation of milk protein expression, and also the increase in p100 
protein levels was demonstrated in these cells. Treatment of HC11 cells with lactogenic 
hormones insulin, glucocorticoids and PRL results in transcription of the β-casein gene (Ball 
et al., 1988; Doppler et al., 1989).  
Broadhurst and coworkers suggested that the modulation of p100 activity in mammary 
gland might occur through post-transcriptional control of expression, since the increase in 
p100 protein abundance occurred without a corresponding increase in p100 mRNA 
(Broadhurst and Wheeler, 2001). However, the role of different lactogenic hormones in up-
regulation of p100 protein was not investigated. To study this phenomenon in more detail, we 
generated an HC11 cell line stable expressing Flag-tagged p100 protein and a control cell line 
with an empty pCIneo vector. Stimulation with Dexamethasone (Dex) alone did not affect the 
p100 protein levels in HC11-p100 cells, while PRL stimulation increased the amount of p100 
protein (Fig. 1). Stimulation with both PRL and Dex did not further affect the p100 levels 
when compared to PRL stimulation. In conclusion, the up-regulation of p100 protein levels is 
mediated by PRL signaling, and Dex is not involved in this regulation. 
We next wanted to investigate whether p100 is involved in the transcriptional 
regulation exerted by Stat5. For this purpose, reporter gene assays were carried out in 
different HC11 cell lines with β-casein promoter driven reporter genes. Cooperation between 
Stat5 and GR is required for the β-casein expression (Stoecklin et al., 1996; 1997), and 
accordingly, in control cells, the stimulation with PRL and Dex resulted in four-fold higher 
induction of the β-casein reporter gene compared to the PRL stimulation (Fig. 2A). 
Interestingly, in HC11-p100 cells, stimulation with PRL and Dex resulted in a two-fold higher 
induction compared to the control cells, suggesting that p100 increases the transcriptional 
activity of Stat5. We further assessed the specificity of p100 action and found that the 
expression of p100 did not affect the activity of NF-κB or C/EBPβ luciferase construct (Figs. 
2D and 2E), indicating that the effect of p100 is targeted to Stat5 activation. 
The half-palindromic GR binding sites at the β-casein gene promoter recruit GR 
molecules to the promoter (Lechner et al., 1997a; 1997b). We next studied whether the effect 
of p100 on Stat5-mediated transcription was dependent on the DNA-binding of GR by using 
serine protease inhibitor (Spi) 2.1-reporter plasmid containing only the Stat5 response element 
of the promoter. We found that the stimulation with both PRL and Dex enhanced the activity 
of the promoter and the stimulatory effect of p100 (Fig. 2C). Since the Spi-luc2 reporter 
construct lacked binding sites for GR, it was likely that the effect of Dex stimulation is 
mediated through a physical protein-protein interaction between Stat5 and GR, as previously 
reported (Stoecklin et al., 1997; Aittomaki et al., 2000). Taken together these results, the 
enhancing effect of p100 on the transcriptional activity of Stat5 is not dependent on the DNA-
binding of GR, but simultaneous activation of GR enhances the stimulatory effect of p100 
possibly through Stat5-GR protein complex formation.  
3.2. p100 does not affect the early activation events or the dephosphorylation rate 
of Stat5 
We next considered at which state of the Stat5 activation-inactivation cycle p100 
exerts its effects. The first activation steps include Stat5 phosphorylation, nuclear localization 
and DNA-binding. p100 might also affect the signal down-regulation through modulating the 
rate of Stat5 dephosphorylation. In normal physiological conditions the activation of 
individual Stat proteins usually lasts from a few minutes to several hours. We used 
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stimulations from 20 min to 20 h to see the effect of p100 during the activation-inactivation 
cycle. Stat5 was rapidly activated, while the inactivation occurred more slowly. The 
expression of p100 did not affect the tyrosine phosphorylation of Stat5 at any time point (Fig. 
3A), nor did it affect the DNA-binding activity of Stat5 (Fig. 3B). These results indicate that 
p100 does not affect the early activation events or the rate of dephosphorylation of Stat5. 
3.3. Stat5 interacts with p100 in vivo and in vitro 
Since p100 had a stimulatory effect on the transcriptional activity of Stat5, we wanted 
to determine whether p100 functioned as a coactivator for Stat5 and interacted physically with 
Stat5. We investigated the potential interaction between p100 and Stat5 in 
coimmunoprecipitation experiments with transiently transfected HC11 cells. As a result, a 
stimulation-independent interaction between p100 and Stat5 was found (Fig. 4A). We then 
characterized the important structural features for this interaction. The SH2 domain is an 
essential element for the activation and function of Stat, docking the protein to tyrosine 
phosphorylated receptor subunits and dimerizing the phosphorylated Stat proteins. In our 
studies, p100 was found to associate also with the SH2 mutant of Stat5A (Fig. 4B). Thus, the 
interaction between p100 and Stat5 is independent of the functional SH2 domain of Stat5. The 
TADs of different Stats have been reported to interact with various coactivator proteins, and 
the Stat5-TAD was earlier shown to associate with p300/CBP (Pfitzner et al., 1998). Stat5A-
TAD, produced as a glutathione-S-transferase (GST) fusion protein, was found to bind to 
p100 in our assays (Fig. 5C). We used Flag-tagged expression constructs consisting of SN-
like domains or TD domain of p100 to characterize the important regions of p100 for the 
interaction. In addition to the full-length p100, Stat5 was found to coimmunoprecipitate with 
both the TD domain and SN-like domains of p100, suggesting that both regions mediate 
association with Stat5 (Fig. 4C). Consistent with the in vivo results, also the GST fusion 
proteins of TD and SN-like domains bound Stat5 (Fig. 5A). Our results show that p100 
functions as a coactivator for Stat5, since it interacts with Stat5 and stimulates the 
transcriptional activity of Stat5. Stat5-TAD and the SN-like and TD domains of p100 mediate 
this interaction. 
 
4. Pim-1 inhibits Stat5 activity (IV) 
A Stat5 target gene pim-1 encodes a serine/threonine kinase that has been found to 
fuction as a survival factor in myeloid cells deprived of IL-3 (Lilly et al., 1999). In addition, 
Pim-1 has been linked to cell mitogenesis and proliferation and to the inhibition of apoptosis 
induced by genotoxic stress (Lilly and Kraft, 1997). The expression of Pim-1 is induced by 
several cytokines including IL-2, IL-3, GM-CSF, EPO, and PRL (Lilly et al., 1992; Lilly and 
Kraft, 1997). Interestingly, it has been proposed that the Stat5-mediated IL-3 response may be 
processed by the products of the Stat5 target genes c-fos and pim-1 (Mui et al., 1996).  
SOCS-1 was first identified as an autofeedback inhibitor of Jaks (Endo et al., 1997). 
As a potent inhibitor of Jaks, the levels of SOCS-1 protein must be tightly regulated. The 
exact mechanism by which the SOCS-1 protein is degraded is not well understood, and 
studies on the interaction between SOCS-1 and Elongin BC have suggested both a role for 
Elongin BC complex in targeting SOCS-1 to the proteasomal degradation pathway (Zhang et 
al., 1999a), and also provided evidence that Elongin BC complex helps to stabilize SOCS-1 
(Kamura et al., 1998). Recently, all three members of the Pim family of kinases were shown 
to bind and phosphorylate SOCS-1 (Chen et al., 2002). Phosphorylation of SOCS-1 by the 
Pim kinases prolonged the half-life of SOCS-1 and potentiated the inhibitory effect of SOCS-
1 on Jak-Stat activation. These data suggested that Pim kinases might regulate Stat signaling 
by modulating SOCS-1 protein levels.  
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4.1. Pim-1 inhibits Stat5 activation, but Stat5 is not a direct substrate for Pim-1 
 Pim-1 can stimulate activities of several transcription factors, such as c-Myb and 
Nuclear Factor of Activated T Cells c (NFATc), and we hypothesized that it might be possible 
for Pim-1 to regulate also the activity of Stat5 (Leverson et al., 1998; Rainio et al., 2002). To 
examine this possibility, we used IL-3-dependent murine myeloid FDCP1 cells stably 
expressing neomycin (FDCP1/Neo) or 44 kDa Pim-1 protein (FDCP1/Pim44) as a cell model. 
In luciferase assay with transiently transfected Stat5-dependent luciferase reporter construct, 
the activity of Stat5 was inhibited by about 50% in FDCP1/Pim44 cells as compared to 
FDCP1/Neo cells after IL-3 stimulation (Fig. 1A), suggesting that Pim-1 kinase had an 
inhibitory effect on Stat5 activity. The expression of the kinase-deficient Lys67Met Pim-1 
mutant returned the activity of Stat5 in FDCP1/Pim44 cells at the levels seen in FDCP/neo 
cells (Fig. 1B), suggesting that the kinase activity of Pim-1 is required for inhibition of Stat5 
activity. By contrast, the 33 kDa wild-type Pim-1 kinase further enhanced the inhibitory 
effects of the 44 kDa Pim-1, implying that the two isoforms of Pim-1 can inhibit Stat5 activity 
in a dose-dependent fashion (Figure 1B). 
To demonstrate that the negative effects of Pim-1 were specific for the Stat5-
dependent reporter and not a result of some general inhibition, we tested also luciferase 
constructs containing multiple NFAT or AP-1 sites in this same cell model. As previously 
observed in Jurkat T-cells transiently expressing Pim-1 protein (Rainio et al., 2002), also in 
FDCP1 cells Pim-1 was able to enhance NFATc-dependent transactivation, while AP-1 
activity was only slightly affected (Fig. 1C). These results indicated that the effect of Pim-1 
on luciferase reporter activities specifically depended on the transcription factors involved. 
Transactivation assays were carried out also with transiently transfected HC11 cells 
stimulated with PRL and HeLa cells stimulated with EPO (Fig. 2 A and B). Ectopic 
expression of Pim-1 inhibited the activity of Stat5 in both cell lines, implying that the 
observed inhibition is not specific for IL-3 signaling or FDCP1 cells only, but that Pim-1 is 
capable of inhibiting Stat5 activation also in other signaling pathways.  
 As Pim-1 inhibited the transcriptional activity of Stat5, we next studied whether Pim-1 
inhibited the early activation events of Stat5 after IL-3 stimulation. The DNA-binding activity 
of Stat5 was lower in FDCP1/Pim44 cells as compared to FDCP1/Neo cells (Fig. 3A). Also 
the degree of tyrosine phosphorylation of Stat5 was reduced in FDCP/Pim44 cells (Fig. 3B). 
These data indicate that Pim-1 inhibits the early activation events of Stat5. 
 Tyr694 is required for the activation of Stat5, but also phosphorylation on Ser725 and 
Ser779 have been observed (Reddy et al., 2000). However, the precise function of Stat5 
serine phosphorylation remains unknown. Since Pim-1 is a serine/threonine kinase, one 
possible mechanism for observed inhibition would be the phosphorylation of Stat5 by Pim-1. 
In in vitro kinase assays GST-Pim-1 fusion protein was not able to phosphorylate a GST 
fusion protein of Stat5-TAD containing both Ser725 and Ser779, or the full-length Stat5 
protein expressed in COS-7 cells (Fig. 4A, and data not shown). In coimmunoprecipitations 
from transiently transfected COS-7 cell lysates, Stat5 interacted with the positive control p100 
as expected (Paukku et al., in press), but did not interact with Pim-1 (Fig. 4B). Similarly, the 
coimmunoprecipitations carried out from FDCP1 cell lysates showed no interaction between 
Pim-1 and Stat5 (data not shown). According to these results, Pim-1 does not bind to Stat5 or 
phosphorylate Stat5. 
4.2. SOCS-1 and SOCS-3 cooperate with Pim-1 to inhibit Stat5 activity 
 Since Pim-1 was able to inhibit Stat5 tyrosine phosphorylation in our studies, and 
Stat5 was not a direct substrate for Pim-1, we hypothesized that another protein must be 
responsible for mediating this effect. According to a recent publication, where Pim-1 was 
found to function through SOCS-1 (Chen et al., 2002), it was possible that the mediator of 
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inhibition could be a member of the SOCS family. To investigate this possibility, the effect of 
SOCS-1, SOCS-2 and SOCS-3 on Stat5 activity was tested in FDCP1/Neo and FDCP1/Pim44 
cells in luciferase assay. All three SOCS proteins were able to inhibit the IL-3-stimulated 
activity of Stat5 in a dose-dependent fashion in FDCP1/Neo cells (Fig. 5, and data not 
shown). However, SOCS-1 and SOCS-3 appeared to be more efficient inhibitors than SOCS-
2. Furthermore, only these two SOCS family members were able to synergize with the 
enforced expression of Pim-1 in FDCP1/Pim44 cells (Fig. 5), resulting in a more profound 
inhibition. These results suggest a specific cooperation between Pim-1 together with SOCS-1 
and SOCS-3.   
 
Even though Pim-1 and SOCS-3 synergized in inhibiting Stat5 activation, the effect 
may still be indirect. It has been demonstrated that Pim-1 phosphorylates SOCS-1 and 
stabilizes the protein (Chen et al., 2002). Because of the high homology between SOCS-1 and 
SOCS-3, it was likely that also SOCS-3 could function as a substrate for Pim-1. Therefore we 
investigated the possible interaction between SOCS-3 and Pim-1 and the ability of Pim-1 to 
phosphorylate SOCS-3. Our results from coimmunoprecipitation assay showed that Pim-1 
indeed interacted with SOCS-3 (Fig. 6A). In addition, wild-type Pim-1 was able to 
phosphorylate SOCS-3 in in vitro kinase assay, whereas the kinase-deficient mutant Pim-1 
was not (Fig. 6B). These results thus suggest that SOCS-3 is a direct substrate for Pim-1.  
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DISCUSSION  
1. PDGF-induced Stat5 activation 
A large number of SH2 domain-containing proteins have been shown to bind to the 
activated PDGF α- and β-Rs. We showed that the stimulation of Swiss 3T3 cells with PDGF 
leads to tyrosine phosphorylation of Stat1, Stat3, and Stat5 (I). The DNA-binding activity of 
Stat6 was detected in NIH3T3 cells, while activation of Stat2 or Stat4 was neither detected in 
Swiss 3T3 cells nor in PAE cells. The Stat-dependent biological signals transduced by the 
PDGFRs are still unknown. The signaling components and receptor amino acid residues 
critical for this study are presented in Figure 11. 
 
 
 
Figure 11. The intracellular part of the PDGF β-R. The critical cellular components and amino acid residues of 
the receptor related to this study are presented. K634 is the critical residue for receptor kinase activity, Y579 and 
Y581 are binding sites for Src and Stat5, and Y775 may also be involved in the binding of Stat5. 
1.1. Role of Src in the PDGF-induced activation of Stat5  
We became interested in studying the activation mechanism of Stat5 by PDGF β-R. At 
the time we started these studies, it was known that Jak and Src kinases become activated 
following PDGF stimulation, but the exact function of these kinases at RTKs remained 
unknown. It was known that Src family kinases are transiently activated by a number of 
growth factors and play important roles in DNA synthesis (Abram and Courtneidge, 2000), 
but little was known about the components of the signaling cascade initiated by Src at RTKs. 
Interestingly, v-Src was described to associate with Stat3 in v-Src-transformed cells and to be 
able to phosphorylate and activate Stat3, and Stat5 was also found to be constitutively active 
in v-Src-transformed cells (Yu et al., 1995; Cao et al., 1996; Chaturvedi et al., 1997). Thus, 
Src was a candidate kinase for tyrosine phosphorylation of Stat5. In our studies, we found c-
Src to be very active in the autokinase assay but a poor activator of Stat5 (II). Taken together, 
our results did not support a direct c-Src-mediated activation mechanism of Stat5 (II). This 
was in line with other studies showing that c-Src, even when highly overexpressed, was a 
considerably less efficient activator of Stat3 than v-Src (Yu et al., 1995). In addition, in 
conditions under which Stat3 coimmunoprecipitated with v-Src, no interaction between v-Src 
and Stat5 could be demonstrated (Chaturvedi et al., 1997), thus Src may be a better activator 
for Stat3 than Stat5. Several studies about whether or not Src activates Stat1, 3 and 6 at the 
PDGFR have been published. According to Wang and coworkers, PDGF-induced Stat3 
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activation is dependent on Src activation, since a specific Src kinase inhibitor inhibited Stat3 
activation following PDGF stimulation (Wang et al., 2000c). On the other hand, 
Sachsenmeier and coworkers have presented that the activation of Stat1, 3 and 6 is 
independent of Src, because the inhibition of Src binding to PDGFR did not abolish the 
activation of these Stats (Sachsenmaier et al., 1999). In contrast, Cirri and coworkers have 
suggested that Src activates both Stat1 and Stat3 at the PDGFR (Cirri et al., 1997). 
Although Src was not responsible for the PDGF-induced phosphorylation of Stat5, it 
could indirectly influence the ability of PDGF β-R to phosphorylate Stat5. Mutation of the c-
Src phosphorylation site Y934 at the PDGF β-R (Hansen et al., 1996) did not affect the 
activation of Stat5 (S. Valgeirsdóttir, unpublished data). In addition, our results obtained with 
fibroblasts deficient in either c-Src or Fyn showed that the PDGF-induced activation of Stat5 
is independent of these Src kinases. In these experiments we could not completely exclude the 
possibility of redundancy in the use of different Src kinases by PDGF β-R; triple knockout 
mice deficient in c-Src, Fyn, and c-Yes would have been needed to address this question.  
For several receptors mediating Stat5 activation, phosphorylation of specific tyrosine 
residues have been shown to be necessary for the activation of Stat5 probably by creating 
binding sites for the SH2 domain of Stat5 (Lebrun et al., 1995; Lin et al., 1995; Demoulin et 
al., 1996; Friedmann et al., 1996; Gobert et al., 1996; Quelle et al., 1996). Tyrosine residues 
579 and 581 were found to be important for tyrosine phosphorylation and DNA-binding 
activity of Stat5 (I). Y579 and Y581 are located in the juxtamembrane domain of the β-R and 
have been shown to serve as binding sites for Src family kinases. Our experiments revealed 
that the SH2 domain of Stat5 was critical for the activation of Stat5 by PDGF β-R. These 
results suggested that inhibition of the phosphorylation of Stat5 by Y579F and Y581F 
mutations is most probably due to the decreased association of the SH2 domain of Stat5 to 
these mutant receptors. Stat5 was retained by immobilized tyrosine phosphorylated receptor 
peptides corresponding to Y579 and Y581, but not to other sites, suggesting that Stat5 may 
bind directly to these sites. The mutation of either Y579 or Y581 in the receptor did not affect 
the ability of the receptor to phosphorylate the Stat5 Y694 site in vitro or the catalytic activity 
of PDGF β-R. The expression of Src-KN resulted in decreased phosphorylation and DNA-
binding of Stat5 in response to PDGF; however, similar inhibition was also seen by 
overexpression of the wild-type c-Src. From our results, we conclude that Stat5 binds to 
PDGF β-R tyrosines Y779 and Y781 and that the activation of Stat5 is independent of Src but 
that Stat5 and Src compete for the same binding sites at the receptor. Similarly, Sachsenmaier 
and coworkers have shown that while the activation of Stat1 and Stat3 is dependent on Y579 
and Y581, the activation of these Stats is not dependent on Src activation (Sachsenmaier et 
al., 1999).  
1.2. Role of receptor tyrosine 775 
Also the mutation of Y775 affected the activation of Stat5 (I). Y775 is located in the 
kinase insert and has been shown to participate in the binding of the small adaptor proteins 
Grb2 and Grb7 to the β-R (Yokote et al., 1996). Y775 is not conserved in the α-R, and it is 
possible that this explains the difference we saw between Stat5 tyrosine phosphorylation 
between α- and β-Rs, β-receptor being a more efficient inducer for Stat5 activation (I). The 
finding that a chimeric PDGF β-R, in which the endogenous kinase insert was replaced with 
the corresponding stretch from the α-R, showed a considerable reduced Stat5 phosphorylation 
in response to PDGF stimulation, supported this notion. Also, Y775 appeared to have the 
weakest affinity for Stat5 based on the phosphopeptide competition data, whereas a mutation 
of this residue in the receptor led to almost equal decrease in the tyrosine phosphorylation of 
Stat5 as in the case of the Y581 mutant. It is possible that even though Stat5 binds to 
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phosphorylated Y579 and Y581 with a higher affinity than Y775, a mutation of Y579 might 
partly be compensated by Y581 and vice versa, making the effect on tyrosine phosphorylation 
of Stat5 weaker, as compared to a singly located mutation of the Y775. We did not further 
study the role of Y775 in binding of Stat5 and the function of Y775 in this respect remains 
open. 
1.3. Jaks at PDGFR 
We showed complex formation between the PDGF β-R and Jak1, Jak2, and Tyk2 (I). 
The PDGF α-R formed a less stable complex with Jak1, whereas complex formation between 
the α-R and Jak2 or Tyk2 was not detected. Jak1 was also tyrosine phosphorylated in 
response to PDGF-BB, whereas tyrosine phosphorylation of Jak2 was not detected in PAE 
cells. In cytokine receptor signaling a wealth of evidence supports a crucial role for Jak 
kinases in the activation of Stats. While the requirement of kinase activity of PDGFR is 
evident, the role of Jaks in activation of the Stat proteins upon PDGF stimulation has 
remained more controversial. Our results suggest that Jaks are not essential to the PDGF-
induced activation of Stat5. Although Jak1 phosphorylated and activated Stat5, expression of 
the kinase negative mutants of Jak1 or Jak2 did not have any effect on the PDGF-induced 
activation of Stat5. Studies in cells defective in expression of specific Jaks, but transfected 
with PDGF or EGF receptors, have indicated that the activation of Stat1 and Stat3 by these 
receptors is not dependent on individual Jaks (Leaman et al., 1996; Vignais et al., 1996). On 
the other hand, the PDGF-induced activation of Stat3 was reported to require Jak kinase 
activity, whereas the activation of Stat1 was independent of Jak activity (Choudhury et al., 
1998; Vignais and Gilman, 1999).  
The function of Jaks in EGFR signaling has been intensively studied. A direct 
interaction between ErbB1 and ErbB2 and Jaks has been detected (David et al., 1996). 
Despite the fact that Jaks are apparently not necessary for Stat activation by EGFRs, it has 
been proposed that they may fulfill other important roles in EGFR signaling. Jaks may serve 
as adaptors for Stats, enabling interaction with EGFRs. The possibility of indirect coupling of 
Stats to EGFRs via constitutively associated Jaks is consistent with the observation that 
autophosphorylation sites on EGFR are not required for the Stat activation (David et al., 
1996). It has also been proposed that because Jaks can be phosphorylated on multiple tyrosine 
residues, they can provide docking sites for phosphotyrosine-binding signaling proteins, 
which, in turn, may serve as substrates for Jak kinases. In addition to Stat activation, Jaks have 
been implicated in the phosphorylation of Shc and the insulin-regulated substrate 1 and 2 (IRS 
1/2) signaling molecules (Johnston et al., 1995; VanderKuur et al., 1995) and in the activation 
of Raf1 and the MAP kinase pathway in response to IFNβ, IFNγ, and OSM (Sakatsume et al., 
1998; Stancato et al., 1998). Immunoprecipitates of Jak1 from IFNβ-, IFNγ-, and OSM-
stimulated cells contained multiple tyrosine-phosphorylated proteins, giving confidence to the 
hypothesis that Jaks may have a function as scaffold molecules. Whether Jaks serve as 
docking sites for phosphotyrosine-binding signaling proteins at the PDGFR or whether they 
have some other important functions, remains to be determined. 
1.4. Direct activation of Stat5 by PDGF β-R 
Our results indicat that the PDGF β-R readily activates Stat5 in mammalian and insect 
cells (II). The results with immune-complex-purified βRic, which was devoid of detectable 
amounts of coprecipitating kinases, confirmed that the PDGF β-R is able to activate Stat5 
directly. After we finished our studies, a direct activation of Stat5 by TEL/PDGFβR and 
purified PDGF-βR kinase domain has been reported (Gesbert and Griffin, 2000; Wilbanks et 
al., 2000; Beisenherz-Huss et al., 2001). Accordingly, PDGF β-R has been shown to activate 
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Stat1 directly in vitro (Choudhury et al., 1998), and also EGFR and InsR have been shown to 
activate Stat factors in vitro (Quelle et al., 1995; Park et al., 1996; Chen et al., 1997). 
Undoubtedly several tyrosine kinase receptors have the ability to activate Stat proteins 
directly.  
1.5. Stats in PDGF signaling 
The different Stat knockout mice have clearly demonstrated that the non-redundant 
functions of different Stats are highly specific for particular cytokines; but the phenotypes are 
different from those of the PDGF-deficient mice (Leveen et al., 1994; Soriano, 1994; Durbin 
et al., 1996; Kaplan et al., 1996; Meraz et al., 1996; Liu et al., 1997; Takeda et al., 1997; Udy 
et al., 1997). The activation of Stat1 and Stat3 by PDGF has previously been compared with 
the activation by IFNα and IFNγ and found to be similar (Silvennoinen et al., 1993b; Raz et 
al., 1994). An example of the possible important involvement of Stats in PDGF signaling is 
the regulation of c-fos expression through the sis-inducible element (SIE) by Stat1 and Stat3 
(Sadowski and Gilman, 1993; Robertson et al., 1995). Stat1 activation often leads to cell 
growth arrest and/or apoptosis (Chin et al., 1996; 1997). However, since cells derived from 
embryos with the Stat1 gene knocked out show a normal mitogenic response to PDGF 
(Durbin et al., 1996; Meraz et al., 1996), Stat1 appears not to be important for the PDGF-
induced mitogenicity. Whether other biological signals transduced by the PDGFRs are 
dependent on Stat1 activation, is currently unclear. It has been proposed that it may be 
important for EGFR to recruit Stat1 in order to balance or restrict Stat3 and/or other 
proliferative or survival signaling pathways by the same receptor that may potentially lead to 
transformation (Chin et al., 1996; Fukada et al., 1996; Chapman et al., 1999). This notion is 
supported by the fact that Stat3 is activated by stimulation with oncogenic PDGF (v-sis) 
(Garcia et al., 1997) and also in tumors with deregulated EGFR signaling. It has been 
suggested that Stat3 activation can serve as a growth-promoting signal in human tumors that 
express high levels of EGFR (Kijima et al., 2002) and Stat3 may promote growth also in 
normal cells. Indeed, in fibroblasts stimulated with PDGF, it was recently shown that Stat3-
mediated c-Myc induction is required for cell cycle progression from G1 to S phase (Bowman 
et al., 2001), and that Stat3 is important in PDGF-induced mitogenesis. Also in vascular 
smooth muscle cells, PDGF-BB-induced expression of cytoplasmic phospholipase A2 
(cPLA2), which is involved in PDGF-induced cell growth, is dependent on the activation of 
Stat3 (Yellaturu and Rao, 2003). 
In our studies, Stat5 was activated in response to PDGF to a similar degree as IL-3-
induced Stat5 activation in hematopoietic cells (I). This suggested that activation of Stat5 in 
response to PDGF is functionally relevant and of consequence for PDGF-induced biological 
responses, but the precise role of Stat5 in PDGF signaling remains unknown. Both Stat5 and 
PDGF have been implicated in the induction of adipocyte differentiation in various models 
(Bachmeier and Loffler, 1997; Udy et al., 1997), and it is possible that the PDGF-mediated 
stimulation of Stat5 is involved in this and similar biological processes. Diverse roles for 
Stat5 have been suggested: loss of Stat5 disrupts IL-2 signaling and results in impaired T-cell 
proliferation and a failure to express genes controlling cell cycle progression (Moriggl et al., 
1999), Stat5 has been linked to cell survival (Schwaller et al., 1998; Socolovsky et al., 1999; 
Schwaller et al., 2000; Ihle, 2001), and to B-cell differentiation induced by IL-4 and IL-7 
(Sexl et al., 2000). In addition, activation of Stat5 by a melanoma inducing EGFR-related 
Xmrk kinase correlated with mitogenic signaling reflected by the cell cycle progression. It 
was suggested that up-regulation of pim-1 expression by Xmrk-activated Stat5 may be 
sufficient to trigger cell cycle progression (Morcinek et al., 2002). One important role for 
Stat5 in PDGF signaling may be mediated through SOCS. PDGF has been shown to induce 
the expression of SOCS-3, most probably via Stat5 (Cacalano et al., 2001). The PDGF-
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induced SOCS-3 functions in the regulation of the Ras/MAP kinase pathway and this role is 
executed through negative regulation of RasGAP, which results in sustained activation of the 
Ras pathway. There is a wealth of evidence indicating that the maintenance of Ras activation 
may control proliferation. Significantly, the Ras/MAP kinase pathway can promote or inhibit 
cell cycle progression, depending on whether its activation is sustained (Woods et al., 1997). 
Prolonged expression and tyrosine phosphorylation of SOCS-3 may have an important role in 
this response.  
Stat3 and Stat5 are clearly involved in the organogenesis of the mammary gland, and 
there is increasing evidence that the Stat proteins are persistently activated in primary breast 
cancers and breast cancer-derived cell lines (reviewed in Garcia and Jove, 1998; Bromberg, 
2000). The potential mechanism(s) responsible for Stat tyrosine phosphorylation in primary 
breast cancer specimens include the overproduction of the EGF and EGFR, PDGFR, Jaks, and 
c-Src, and perhaps mutations within the Stat protein (Garcia et al., 1997; Garcia and Jove, 
1998; Sartor et al., 1997). Interestingly, the myeloproliferative phenotype, induced in mice by 
TEL/PDGF β-R expression, depends on the PDGF β-R tyrosines 579 and 581 (Tomasson et 
al., 2000). It was speculated that this dependence is due to the Src binding, but in light of our 
results, it might also result from Stat5 binding to the receptor. Evidently, also PDGF-induced 
activation of Stats may mediate signals for transformation by PDGF. 
 
 
2. p100 functions as a coregulator for Stat5 
Several hormones and factors influence milk protein gene expression in mammary 
epithelial cells, but the best understood are PRL and glucocorticoids. Their signals are 
mediated through transcription factors, which act on the promoters of the milk protein genes. 
In this regard, several transcription factors including Stat5, GR, NF-kB, NF-1, and C/EBP 
(Raught et al., 1994; Li and Rosen, 1995; Liu et al., 1996; Stocklin et al., 1996; Lechner et 
al., 1997b; Geymayer and Doppler, 2000) have been studied. However, a clear overall picture 
of how the transcriptional control of milk protein genes is achieved throughout the gestation-
lactation cycle is yet to come to light. It is probable that all transcriptional activators or 
coactivators that are also involved have not yet been studied in this context. The abundance of 
mammary p100 during the gestation-lactation cycle was shown to be specifically and closely 
associated with lactation. Interestingly, the increased p100 abundance during lactation appears 
to be a common feature among mammals. The physiological role of p100 in PRL signaling 
had not been earlier studied. 
2.1. Functional interaction between p100 and Stat5 
The findings that p100 protein levels increased during lactation and that p100 was 
present in lipid droplets of milk secreting cells, suggested that p100 might participate in the 
regulation of milk gene induction. We observed that p100 enhanced the transcriptional 
activity of Stat5 and interacted with Stat5, which indicated that p100 functions as a 
coactivator for Stat5. Association between p100 and Stat5 did not require tyrosine 
phosphorylation or functional SH2 domain of Stat5. Since p100 has been detected in both the 
cytoplasm and nucleus, the interaction could occur already in the cytoplasm, and p100 and 
Stat5 could translocate to the nucleus as a complex. Phosphorylation of Stats is not always 
required for their interactions with coregulators, and for example interaction of Stat5 with GR 
or Stat6 and p100 is independent of tyrosine phosphorylation of Stats (Wyszomierski et al., 
1999; Yang et al., 2002). We found an interaction between Stat5-TAD and p100, but it is 
possible that also other regions of Stat5 mediate the interaction with p100.  
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The structure of p100 consists of four repeated domains with similarity to the 
staphylococcal nuclease structure SN-like domains, and a TD domain (Callebaut and Mornon, 
1997; Ponting, 1997a). The TD domain of p100 is a “hybrid” SN-like domain, where a 
domain, which is found in multiple copies in the Drosophila melanogaster Tudor protein, 
replaces the OB-fold. Staphylococcal nucleases (SNs) are small calcium-dependent enzymes, 
which hydrolyze both DNA and RNA. SNs consist of two subdomains, of which the first 
subdomain belongs to the large oligonucleotide/oligosaccharide-binding (OB)-fold 
superfamily (Murzin, 1993), and the second subdomain consists of two independently folded 
α-helices. The SN-like domains of p100 lack the catalytic amino acids present in nucleases. 
We found that the SN-like domains of p100 mediate interaction with Stat5. The SN-like 
domains of p100 have been shown to contain EVES sequence, which is able to interact with 
c-Myb and inhibit its activity (Dash et al., 1996). In addition, p100 interacts with Pim-1 
serine/threonine kinase through a sequence located in SN-like domains, but different from 
EVES (Leverson et al., 1998), indicating that there are several protein interaction motifs in 
the SN-like domains of p100. Only the SN-like domain of p100 was found to mediate the 
interaction with Stat6 (Yang et al., 2002), but we showed that also the TD domain of p100 
associates with Stat5 and can therefore function as a protein interaction domain (III). TD 
domains are conserved protein modules of unknown function that are often present in proteins 
that associate with RNA (reviewed in Ponting, 1997b). The determined structure of the TD 
domain of Survival of Motor Neuron (SMN) protein suggests, however, that TD domains 
function as protein interaction motifs and do not bind to RNA directly (Selenko et al., 2001). 
In line with this hypothesis and our results, the TD domain of SMN protein has been found to 
mediate interactions with a spliceosomal Sm core protein (Selenko et al., 2001), and with a 
small nucleolar RNA-associated protein fibrillarin (Jones et al., 2001). In addition, two TD 
domains of Trap protein (tudor repeat associator with PCTAIRE 2) have been shown to 
associate with a Cdc2-related kinase PCTAIRE 2 in rat brain (Hirose et al., 2000).  
2.2. p100 in PRL signaling 
In our assay, the proper stimulation of the β-casein promoter required the activation of 
GR, while the enhancing effect of p100 appeared not to require GR. Activation of GR, 
however, enhanced the stimulatory effect of p100 and this effect was not dependent on the 
DNA-binding of GR. Stat5 and GR physically interact with each other, and this protein 
complex may mediate a more stable interaction surface with p100 than the relatively small 
TAD of Stat5 alone. C/EBPβ activates β-casein expression in synergy with Stat5 and GR, and 
several binding sites for C/EBP have been mapped in the β-casein gene promoter (Doppler et 
al., 1995). Also NF-κB has a binding site at the β-casein promoter, and NF-κB has been 
shown to negatively regulate the β-casein gene expression by inhibiting the activity of Stat5 
(Geymayer and Doppler, 2000). We showed that p100 had no effect on the transcriptional 
activity of C/EBPβ or NF-κB, therefore demonstrating the specificity of p100 on Stat5-
mediated activity.  
Several mechanisms, by which p100 could modulate the transcriptional activity of 
Stat5, existed. The increased tyrosine phosphorylation and/or DNA-binding can stimulate 
transcriptional activity, as has been observed in Stat5-GR cooperation (Wyszomierski et al., 
1999). We did not observe any changes in the early steps of Stat5 activation by p100. Serine 
phosphorylation has been implicated in the regulation of Stat activity, and phosphorylation of 
Stat1 and Stat3 on serine within their TAD is needed for maximal IFN-induced transcriptional 
activation (Wen et al., 1995; Zhang et al., 1995; Bromberg et al., 1996; Horvath and Darnell, 
1996; Ng and Cantrell, 1997). In the Stat5-TAD, there are two proline-juxtaposed serine 
residues, which become phosphorylated in the mammary gland during gestation and lactation. 
Several serine/threonine kinases are activated upon PRL stimulation, but the kinase 
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phosphorylating Stat5 is currently unknown (Yamashita et al., 2001). However, serine 
phosphorylation of Stat5 in the mammary gland has an inhibitory effect on the transcriptional 
activity of Stat5 (Yamashita et al., 2001), and therefore it is unlikely that the function of p100 
would be to recruit a serine kinase to Stat5. Modulation of the chromatin structure by histone 
acetylation is critical for the activation of transcription, and several coactivators, like 
p300/CBP, possess HAT activity. p100 has earlier been shown to be devoid of HAT activity 
(Wang et al., 2000b), and the function of p100 does not appear to involve direct modulation 
of chromatin structure. Coactivators can also function as bridging factors to the basal 
transcription machinery. p100 was found to increase the IL-4-induced transcriptional activity 
of Stat6 possibly by bridging Stat6 to RNA polymerase II (Yang et al., 2002). It is thus likely 
that p100 mediates a similar function in Stat5 by bridging it with the basal transcriptional 
machinery. 
We found that p100 levels were increased after PRL stimulation. The high abundance 
of p100 during lactation and its ability to cooperate with Stat5 originally suggested to us that 
p100 might be involved in milk protein gene expression. The modulation of p100 activity in 
mammary epithelial cells occurs likely through post-transcriptional control of expression, 
since the increase in p100 protein abundance occurs without a corresponding increase in p100 
mRNA (Broadhurst and Wheeler, 2001). These results together with our findings 
demonstrating the costimulation of Stat5-mediated transcription by p100, suggest the 
existence of a positive regulatory loop in PRL-induced transcription, where PRL stabilizes 
p100 protein, which in turn can cooperate with Stat5 in transcriptional activation of the β-
casein gene promoter, and probably also in other Stat5-regulated milk gene promoters.  
Diverse, cell type and cytokine specific interactions between Stat factors and non-Stat 
transcription factors might contribute to the different phenotypic effects elicited by individual 
cytokines utilizing the Jak/Stat pathway.  
 
3. Pim-1 negatively regulates the activity of Stat5 
3.1. Cooperation between Pim-1 and SOCS proteins  
Studies with both the transcriptionally inactive TAD deletion construct of Stat5 and 
the hyperactivated mutant Stat5 have shown that the expression of several genes, including 
cis, osm and pim-1, is dependent on Stat5 (Mui et al., 1996). Under physiological conditions, 
cytokine stimulation first results in an activation phase, which is then quickly quenched by 
negative regulators such as CIS, SOCS, p21WAF1/Cip1, and tyrosine phosphatases. Interestingly, 
Stat5 has been shown to be able to regulate both phases. SOCS proteins are encoded by 
immediate early genes that act in a feedback loop to inhibit cytokine responses and activation 
of Stats. The constitutive expression of SOCS-1 was shown to be sufficient to induce 
apoptosis of Ba/F3 cells, whereas constitutive expression of Pim-1 was sufficient to induce 
IL-3-independent growth of Ba/F3 cells (Nosaka et al., 1999). These findings suggested that 
Stat5 might regulate cell fate by varying the intensity and duration of the expression of a set of 
target genes. The Pim kinases and SOCS proteins are induced by a variety of cytokines, and 
the interaction between Pim and SOCS may represent a mechanism by which cytokines cross-
regulate one another. For example, expressions of Pim-1, Pim-2, and SOCS-1 are all induced 
by IFNγ (Yip-Schneider et al., 1995; Starr et al., 1997), and the interplay between Pim 
kinases and SOCS-1 may be important for IFNγ-induced inhibition of IL-4 signaling 
(Dickensheets et al., 1999; Venkataraman et al., 1999).  
In our studies, we found that Pim-1 inhibits the transcriptional activity of Stat5 in IL-3, 
PRL, and EPO signaling, and that the kinase activity of Pim-1 is required for this inhibition. 
The inhibition was seen at the levels of tyrosine phosphorylation, DNA-binding and 
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transactivation of Stat5. However, Pim-1 did not interact with Stat5 or phosphorylate Stat5, 
which encouraged us to study whether another protein might cooperate with Pim-1 in the 
inhibition of Stat5 activity. Interestingly, SOCS-1 and SOCS-3, and to lesser extent SOCS-2, 
were found to further enhance the negative effects of Pim-1 on Stat5 activity. According to 
our results, SOCS proteins most likely mediate the observed inhibitory signal of Pim-1. We 
demonstrated that SOCS-3 is a direct substrate for Pim-1. In accordance with our results, 
SOCS-1 was earlier published to interact with Pim-1 and be phosphorylated by Pim-1 (Chen 
et al., 2002). It is also possible that Pim-1 affects other Stats, especially since both Stat5 and 
Stat3 have recently been reported to be able to complement Pim-1 and Pim-2 in tumorigenesis 
(Mikkers et al., 2002), and since Pim-1 has been reported to inhibit Stat6 activation after IL-4 
stimulation in cooperation with SOCS-1 (Chen et al., 2002) . 
SOCS-1 was earlier shown to be stabilized by Pim-1. It is therefore possible that Pim-1 
stabilizes also SOCS-3 by serine phosphorylation, and thereby potentiates its inhibitory 
effects. In this respect, it is interesting to note that the SOCS-3 function and stability can be 
regulated also by tyrosine phosphorylation. SOCS-3 is rapidly tyrosine phosphorylated after 
IL-2 stimulation, and also after various growth factor stimulations (Cohney et al., 
1999;Cacalano et al., 2001). The tyrosine phosphorylated SOCS-3 can interact with RasGAP, 
maintain activation of ERK, and ensure cell survival and proliferation through the Ras 
pathway (Cacalano et al., 2001). The phosphorylation was also shown to inhibit the SOCS-3-
elongin C interaction and activate proteasome-mediated SOCS-3 degradation  (Haan et al., 
2003).  
Our results suggest that Stat5 may attenuate its own activation via the up-regulation of 
its target gene pim-1. This negative feedback loop may therefore regulate cell survival, 
proliferation, and differentiation. Because Pim-1 does not completely inhibit Stat5 activation, 
the observed inhibition may be a fine-tuning mechanism that maintains the Stat5 activity at an 
optimal level. During malignant transformation, forced activation of Stat5 may lead to 
activation of both proliferative genes, such as c-myc, and survival genes, such as pim-1, so 
that the inhibitory signal is overridden.  
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 PERSPECTIVE 
 
Stat5 functions as a downstream effector of cytokine and growth factor receptor 
signaling. Pleiotropic gene regulation by Stat5 has been implicated in cellular functions such 
as proliferation, differentiation, and apoptosis with relevance to processes of hematopoiesis 
and immunoregulation, reproduction, and lipid metabolism. Compared with normal cells and 
tissues, constitutively activated Stat5 has been identified in a wide variety of human cancer 
cell lines and primary tumors. In tumor cells, Stat5 activity is linked to persistent activity of 
tyrosine kinases, including Src, EGFR, and PDGFR. Persistent activation of Stat5 has been 
demonstrated to directly contribute to oncogenesis by stimulating cell proliferation and 
preventing apoptosis. Interestingly, in fatal myeloproliferation, induced in mice by 
TEL/PDGF β-R expression, the myeloproliferative phenotype requires PDGF β-R tyrosines 
579 and 581. According to our results, the phenotype may be dependent on the activation of 
Stat5. The function of Stats in PDGF signaling is still largely unknown, but the consequences 
of Stat activation in both normal PDGF signaling as well as in malignant cells are important 
aspects for future studies. 
As important as it is to characterize the mechanisms for Stat activation, is to clarify the 
specific cascades for Stat signal down-regulation. Stat activation is inhibited by 
dephosphorylation, but also by SOCS proteins, which can block the Stat activation by 
inhibiting Stat receptor binding or Jak activity. In our studies, it was found that a Stat5-
induced protein Pim-1 could regulate the activity of Stat5 by cooperating with SOCS proteins. 
Interestingly, our data indicated that Pim-1 together with SOCS-1 and SOCS-3 are likely to 
be components of a negative feedback loop that allows Stat5 to inhibit its own activation. In 
the future, gene expression profiling by microarray technology is expected to reveal a 
molecular signature of Stat5-regulated genes and enable the subsequent studies for finding the 
specific functions of Stat target genes.  
In this study p100 was identified as a Stat5 coactivator. Increasing knowledge of how 
Stat proteins affect transcriptional regulation is important as basic information for 
understanding the coordinated control of transcription in mammalian cells. In addition, it is 
necessary to know the most common interacting partners of specific transcription factors if 
pharmacological intervention of specific transcriptional activity is to be achieved. One of the 
attractive features of Stat proteins for cancer therapy is that there are only two molecular 
targets, Stat3 and Stat5, as opposed to a huge number of tyrosine kinases. As a matter of fact, 
in many cases it has been demonstrated that blocking Stat3 or Stat5 function alone is 
sufficient to inhibit tumor cell growth and to induce apoptosis. The interest for developing 
inhibitors of Stat5 for molecular-targeted cancer therapy is accelerating, as the importance of 
Stat5 in human cancer is becoming increasingly evident. 
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